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Abstract 
Supporting Clinician Decision Making in Cancer Care Delivery 
Melissa Parsons Beauchemin 
Background 
Cancer treatment and management require complicated clinical decision making to 
provide the highest quality of care for an individual patient. This is facilitated in part with ever-
increasing availability of medications and treatments but hindered due to barriers such as access 
to care, cost of medications, clinician knowledge, and patient preferences or clinical factors. 
Although guidelines for cancer treatment and many symptoms have been developed to inform 
clinical practice, implementation of these guidelines into practice is often delayed or does not 
occur. Informatics-based approaches, such as clinical decision support, may be an effective tool 
to improve guideline implementation by delivering patient-specific and evidence-based 
knowledge to the clinician at the point of care to allow shared decision making with a patient and 
their family. The large amount of data in the electronic health record can be utilized to develop, 
evaluate, and implement automated approaches; however, the quality of the data must first be 
examined and evaluated. 
Methods 
This dissertation addresses gaps the literature about clinical decision making for cancer 
care delivery. Specifically, following an introduction and review of the literature for relevant 
topics to this dissertation, the researcher presents three studies. In Study One, the researcher 
explores the use of clinical decision support in cancer therapeutic decision making by conducting 
a systematic review of the literature. In Study Two, the researcher conducts a quantitative study 
to describe the rate of guideline concordant care provided for prevention of acute chemotherapy-
induced nausea and vomiting (CINV) and to identify predictors of receiving guideline 
concordant care. In Study Three, the researcher conducts a mixed-methods study to evaluate the 
completeness, concordance, and heterogeneity of clinician documentation of CINV. The final 
chapter of this dissertation is comprised of key findings of each study, the strengths and 
limitations, clinical and research implications, and future research. 
Results 
In Study One, the systematic review, the researcher identified ten studies that 
prospectively studied clinical decision support systems or tools in a cancer setting to guide 
therapeutic decision making. There was variability in these studies, including study design, 
outcomes measured, and results. There was a trend toward benefit, both in process and patient-
specific outcomes. Importantly, few studies were integrated into the electronic health record. 
In Study Two, of 180 patients age 26 years or less, 36% received guideline concordant 
care as defined by pediatric or adult guidelines, as appropriate. Factors associated with receiving 
guideline concordant care included receiving a cisplatin-based regimen, being treated in adult 
oncology compared to pediatric oncology, and solid tumor diagnosis.  
In Study Three, of the 127 patient records reviewed for the documentation of 
chemotherapy-induced nausea and vomiting, 75% had prescriber assessment documented and 
58% had nursing assessment documented. Of those who had documented assessments by both 
prescriber and nurse, 72% were in agreement of the presence/absence of chemotherapy-induced 
nausea and vomiting. After mapping the concept through the United Medical Language System 
and developing a post-coordinated expression to identify chemotherapy-induced nausea and 
vomiting in the text, 85% of prescriber documentation and 100% of nurse documentation could 
be correctly categorized as present/absent. Further descriptors of the symptoms, such as severity 
or temporality, however, were infrequently reported.  
Conclusion 
In summary, this dissertation provides new knowledge about decision making in cancer 
care delivery. Specifically, in Study One the researcher describes that clinical decision support, 
one potential implementation strategy to improve guideline concordant care, is understudied or 
under published but a promising potential intervention. In Study Two, I identified factors that 
were associated with receipt of guideline concordant care for CINV, and these should be further 
explored to develop interventions. Finally, in Study Three, I report on the limitations of the data 
quality of CINV documentation in the electronic health record. Future work should focus on 
validating these results on a multi-institutional level. 
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Chapter One: Introduction 
Chapter One outlines the organization and background of this dissertation. It begins by 
describing cancer care in the United States (US) and then focuses on a specific patient 
population: children, adolescents, and young adults with cancer. Challenges with treating these 
patients, specifically related to symptom management are then discussed. A specific symptom, 
chemotherapy-induced nausea and vomiting is explicitly discussed including the prevalence, 
impact on patients, and availability of clinical practice guidelines that provide prevention and 
management strategies. Barriers to guideline implementation are then outlined, both generally, 
but also specifically related to supportive care guidelines in children, adolescents, and young 
adults with cancer. Then the background shifts to describe strategies that may improve 
implementation of guidelines, specifically using informatics-based approaches such as clinical 
decision support. The increasing use of electronic health records and the importance of 
integrating decision support as well as patient-reported information into the electronic health 
record are discussed. The theoretical framework utilized in this research is then described, and 
finally, the plan for three manuscripts and their respective aims are summarized.  
The first manuscript (Chapter Two) is currently under revisions for the International 
Journal of Medical Informatics. The second manuscript (Chapter Three) is planned for 
submission to Supportive Care in Cancer. The third manuscript (Chapter Four) is planned for 
submission to the Journal of American Medical Informatics Association.  
Current Complexities in Cancer Treatment 
40% of the US population will be diagnosed with cancer during their lifetime, and 
although the treatment and prognosis depends on the type and stage of cancer, the majority of 
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cancer patients will undergo intensive treatment either for curative or palliative intent.1  
Although many cancers have clear treatment guidelines available, decision-making for cancer 
treatment is complex.  First, the era of precision medicine and genomic testing has introduced a 
treatment landscape often with one or more possible treatment options.2  Second, factors such as 
patient age, clinical or performance status, and a patient’s insurance status may influence the 
prescribed treatment plan.3,4 Finally, our ability to predict, diagnose, and treat both cancer- and 
therapy-related toxicities has improved greatly, further complicating decision making to 
individualize each cancer patient’s treatment plan.  During treatment, following treatment, or at 
time of relapse, additional decision-making time points occur, and providers are expected to have 
the most updated information to inform shared decision making with a patient and their family.   
Cancer treatment is also associated with significant side effects. Treatment modalities 
include chemotherapy, targeted therapies, radiation therapy, and/or surgery.  These treatments 
are often intensive and associated with significant acute side effects and long-term morbidity, 
such as nausea, vomiting, fatigue, infection, chronic pain, neuropathy and cardiac 
complications.5-7 These and other side effects of therapy negatively impact a patient’s symptom 
experience and quality of life.7-9 Poorly-controlled symptoms may also cause a delay in curative 
treatment or non-adherence to the treatment plan, jeopardizing a patient’s survival.10,11  Many of 
these treatment-related symptoms, however, can be palliated, and a substantial body of evidence-
based research exists to provide guidance on the best practices for prevention and treatment of 
many cancer-related symptoms.12-17  There is unfortunately a wide variability in clinical settings, 
and these guidelines are not consistently implemented in practice.18,19   
In addition to the challenges of clinically managing an individual cancer care, the burden 
of cancer continues to increase.  With an aging population, although the proportion of new cases 
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of cancer is stable or decreasing, the overall number of patients continues to increase. In 
addition, the Affordable Care Act has improved access to care in the US, reducing the uninsured 
rate by 43% from 2010 to 2015.  The US healthcare system, therefore, now has more patients 
with access to care without an equivalent influx of providers,20 contributing to an increasing 
workload for prescribers and other clinicians.  The costs of cancer are also significant, with 
treatment-related expenses accounting for 9% of prescription spending for Americans and 
another 3% or $11.1 billion spent on supportive care medications to alleviate treatment-related 
symptoms.21   
Pediatric, Adolescent and Young Adult Cancers 
Since the 1970’s, the survival rates for most types of pediatric and adolescent cancers 
have improved with about 80% of pediatric patients now expected to become long-term 
survivors (at least 5 years from diagnosis).22  These successes, however, require intensive and 
frequent therapy that is often the cause of significant side effects and morbidity.23 The majority 
of children with cancer experience bothersome side effects during their treatment, most 
commonly fatigue, nausea, and pain.6,24-26  Similar to adult data, increased symptoms in younger 
patients are also associated with poorer psychological outcomes and health-related quality of 
life.27 Due to the high cure rates in childhood cancers, however, these symptoms and their 
potential negative effect on long-term outcomes are sometimes overlooked due to the importance 
of and likelihood of cure.28 
For adolescents and young adults with cancer, broadly defined as ages 15 – 39 years of 
age, the survival outcomes are less optimistic than their younger counterparts with the same 
types of cancer.29  In addition to biologic differences in disease, a significant reason for poorer 
survival for adolescents and young adults is they do not tolerate the pediatric regimens as well as 
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younger children and experience more side effects and symptom burden.30-32  Erickson et al32 
conducted a review of symptoms in adolescents receiving chemotherapy and found that 
adolescents experience multiple distressing symptoms during chemotherapy, including fatigue, 
sleep disturbances, pain, nausea/eating problems, mood disturbances, and appearance changes. A 
qualitative study of adolescents and young adults identified symptoms, specifically pain, nausea, 
and vomiting, as a significant concern during cancer treatment.33  Although there is a wide age 
range, the importance of developmental milestones, such as formal cognition, independence, and 
sense of self may be hindered due to a cancer diagnosis and necessary treatment.34 In addition, 
adolescents and young adults with cancer may experience logistical challenges affecting their 
ability to adhere to treatment and symptom management recommendations. These include poorer 
access to care due to transportation challenges, poorer insurance coverage, and less direct 
support from parents, family, and peers.35,36   
Chemotherapy-induced Nausea and Vomiting 
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common 
treatment-related symptoms affecting up to 80% of all cancer patients.6,27,37  It is also cited by 
patients as one of the most feared adverse effects of cancer treatment.6,38,39  Chemotherapy is 
classified by emetogenicity, or its propensity to cause nausea and/or vomiting;40-42 most 
commonly the classes are high (emetic risk >90%), moderate (30-90%), low (10-30%), and 
minimal (<10%). In addition to the cause, CINV is classified temporally as acute, delayed, 
anticipatory, and breakthrough or refractory.43  Risk factors in adult cancer patients have been 
identified and include gender (female > male),44 age (< 55 years),45 cycle of chemotherapy 
(initial > subsequent),46 prior morning sickness with pregnancy, and alcohol intake.47   
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In children with cancer, little is known about risk factors outside of the emetogenic 
potential of the chemotherapeutic agents.  A study of children with acute myeloid leukemia 
found a significant association of antiemetic alteration, a validated proxy measure for the 
experience of CINV, and increasing age (P<.001).48  In addition, this study found that the rate of 
antiemetic rescue, providing an adjunct therapy for treatment of CINV, in privately insured 
patients compared with publicly insured patients was significantly lower, suggesting a disparity 
in how CINV is assessed and/or managed. 
Although risk factors for CINV in children with cancer are less well understood, studies 
have found it is a common and persistent cancer-related symptom. A longitudinal study of 
children with standard-risk acute lymphoblastic leukemia (ALL) assessed common symptoms 
over time, including procedure- and treatment-related anxiety, pain, and nausea by parental 
report, and it found that nausea was among the most common symptoms with 47% of patients 
reporting it at the start of the study.  In addition, although most symptoms improved over the 
course of treatment, the mean score of nausea was significantly worse at both 6- and 12-months 
after diagnosis compared with 1-month after diagnosis (P<.0001).49  This is important for three 
reasons: first, it highlights the persistence of CINV as a symptom and the difficulty in achieving 
complete control for many patients; second, patients who have poorly controlled nausea with 
their first chemotherapy administration have an increased likelihood of refractory, breakthrough, 
and anticipatory nausea;50 and third, it suggests that screening for nausea may be less frequent in 
later phases of treatment, and therefore, treatments less frequently prescribed or administered.  
 In studies of adolescents with cancer, CINV has been reported in 50 – 100% of patients 
receiving chemotherapy.32 Less is known about the prevalence and severity of symptoms in 
young adults; however, a qualitative study to explore issues experienced by young adults during 
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cancer treatment reported that 84% of participants cited symptoms as the most important factor 
affecting health-related quality of life.33 In addition, it is well-established that adolescent and 
young adults with cancer have poorer survival outcomes51 compared to younger pediatric 
patients, often attributed to lower rates of health insurance coverage,52 lower rates of 
participation in clinical trials,53 and poorer biology of cancer.54  Insurance status directly relates 
to access to care, including supportive care measures, and because treatment adherence can be 
affected by symptoms like CINV, it is important to optimally manage symptoms as this may help 
to improve survival. 
Clinical Practice Guidelines 
Although cancer treatment and management are complex, effective strategies to predict, 
prevent, identify, and manage cancer have been described in the literature.  Many of this 
guidance comes from clinical practice guidelines, defined by the Institute of Medicine in a 2011 
report as “statements that include recommendations intended to optimize patient care that are 
informed by a systematic review of evidence and an assessment of the benefits and harms of 
alternative care options.”55  Guidelines are developed through a rigorous systematic methodology 
synthesizing the ever-increasing amounts of published literature into a practical and digestible set 
of clinical recommendations to be used in a healthcare setting.56,57  The Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) collaboration developed 
a widely-accepted approach for developing guidelines by rating both the quality of the evidence 
and the strength of the recommendation.58 The U.S. Preventive Services Task Force also 
develops guidelines using a similarly rigorous and transparent methodology.59  Both recognize 
that guidelines need to be trustworthy and understandable, and the goal is to direct clinicians in 
providing the most up-to-date, evidence-based, and highest quality care for their patients.   
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Chemotherapy-induced Nausea and Vomiting Guidelines 
Poor management of symptoms, specifically CINV, is particularly worrisome because 
medications are available to effectively prevent or manage it.  Robust guidelines have been 
developed for the prevention and treatment of CINV both for adult and pediatric cancer 
patients.60-62  Provision of guideline concordant care (GCC) improves patient symptoms, as 
demonstrated in a study where GCC was provided to adult patients. Complete response (i.e. no 
symptoms of nausea or vomiting) was achieved in a significantly higher number of patients 
receiving GCC compared with those receiving guideline-inconsistent care (aOR 1.43; CI95 1.04 – 
1.97).63
For pediatric cancer patients, all available guidelines recommend that children receiving 
highly- or moderately-emetogenic chemotherapy (HEC or MEC) receive a 5HT3-blocker (e.g. 
ondansetron, granisetron) and dexamethasone, a corticosteroid, for prevention of CINV.61,64  In 
addition, for patients receiving HEC, an additional class of medications, neurokinase inhibitors 
(NK1RAs) (e.g. aprepitant, fosaprepitant), are also recommended. The 2013 guideline for 
pediatric patients restricted this recommendation only to patients greater than age 12 years; 
however, the updated 2017 guideline for CINV prevention in pediatric cancer patients 
recommends an NK1RA for anyone receiving HEC older than 6 months of age.61  In adults, the 
guideline recommendations are similar, recommending a 5HT3-blocker and dexamethasone to 
prevent acute CINV in patients receiving MEC, and the addition of an NK1RA for patients 
receiving HEC.62,65 
Disparities in the Delivery of Guideline Concordant Care 
 There is wide variability in clinical practice, however, and providers do not consistently 
follow these guidelines.18  Two studies examining adherence to guideline recommendations for 
CLINICAL DECISION MAKING IN CANCER CARE 
8 
prevention of CINV in adult cancer patients demonstrated racial and socioeconomic disparities in 
receipt of GCC. A recent study of breast cancer patients found that 60% of patients did not 
receive the recommended prophylactic treatment for CINV. They also demonstrated a racial 
disparity with black women being significantly less likely to receive NK1RAs than white women 
(aRR=0.68, 95 % CI 0.51–0.91; P<.05).66  Another study of newly-diagnosed lung cancer 
patients found that individuals in the highest income quartile had significantly higher likelihood 
of receiving National Comprehensive Cancer Network-recommended CINV treatment compared 
with those in the lowest income quartile (OR=1.622; 95% CI 1.367-1.924; P < .001).67 
In pediatric, adolescent and young adults with cancer, studies have shown that 
administration of an appropriate antiemetic significantly reduces both nausea and vomiting.18,68  
These studies, however, described the efficacy of antiemetic treatment in controlled clinical trials 
and did not examine the proportion of patients receiving GCC in a real world setting.  Little is 
known about the predictors of children, adolescents and young adults receiving GCC. This is 
important to understand given that there are effective treatments for CINV, and not adhering to 
the guidelines may worsen patient symptoms, increase risk of dehydration, decrease patient-
reported quality of life, and worsen adherence with prescribed treatment regimen.49,69,70 
Challenges in Guideline Implementation 
Although our literature is replete with guidelines, the expected improvements in patient 
outcomes and reduction in healthcare-related costs have not followed.56,71,72 Studies have 
demonstrated that on average, it takes 17 years for 14% of knowledge to be translated into 
clinical practice,73,74 and in response to this, research has broadened to focus on how guidelines 
can be effectively implemented in a clinical or community setting.75,76  The transdisciplinary 
field of implementation science has been established, and the complexities of translating 
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evidence into practice are numerous.  For example, the Expert Recommendations for 
Implementing Change (ERIC) project76 named 73 implementation strategies, highlighting the 
extensiveness and complexity of implementation studies.  These strategies aim to enhance the 
adoption, implementation, and sustainability of a clinical program or practice.77,78 This area of 
research requires an ongoing, iterative and constant feedback mechanism. These studies, 
therefore, include outcomes that differ from traditional research outcomes such as efficacy or 
effectiveness, and instead highlight the acceptability, appropriateness, costs, and sustainability of 
the implementation strategy.79,80   
Because of the time lag identified in implementing research into practice, research on the 
barriers to implementation have also been published.71,81 Barriers are similarly complex and may 
vary by the implementation strategy being utilized, setting characteristics, provider and cultural 
characteristics, and the evidence or practice change that is being implemented.  Factors 
associated with guideline adherence include provider-level, system or hospital-level, patient-
level characteristics as well as provider-patient communication.82,83 The greatest likelihood of 
implementation of guidelines into clinical settings is seen through multi-level approaches that 
integrate outcomes such as acceptance into practice, sustainability, and even deimplementation 
of practices that are determined to no longer be effective or appropriate.84 
Clinical Decision Making 
Clinical decision making is a complex process and requires clinicians to harness large 
amounts of patient-generated and evidence-based data to provide the best care.85,86  This is 
challenging, however, and studies have shown that clinicians may over- or underestimate the 
risks and benefits of available treatment.87 In addition to synthesizing the available evidence, 
clinicians should make treatment decisions with consideration of patient preferences.  This shift 
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toward patient-centered care ideally leads to shared decision making, a model of care that may 
help to improve care and reduce healthcare costs.88 Shared decision making involves the patient, 
often family members, and clinician(s) working as a team to make the most appropriate decision 
for an individual patient.  This model is especially useful when more than one option for care 
exists.  One can argue that this is found in most healthcare settings, as continued advances in 
medicine and precision health allow for multiple and tailored treatment options.89,90 
The availability of more than one treatment option, however, leads to increasingly 
complicated decision making in a healthcare system where it is challenging to have enough time 
and resources to make the best decision for each individual patient while incorporating cultural, 
religious, and other personal considerations.91  It is important to identify strategies that can 
harness these data and considerations in support of clinicians to provide cancer patients the 
highest quality of treatment and supportive care.  Previous research has shown that computerized 
clinical decision support systems have the potential to successfully support this goal.92,93 
Clinical Decision Support 
Clinical decision support (CDS) should  “provide clinicians, staff, patients, or other 
individuals with knowledge and person-specific information, intelligently filtered or presented at 
appropriate times, to enhance health and health care.”94 The premise for CDS is not that the 
technology should replace the clinician and make the decision, but that, due to the huge amount 
of information available in healthcare settings, the technology can serve as a guide or support to 
help the clinician to make the right decision for the right patient at the right time.86 Three 
concepts, or pillars, are required to give CDS the best chance of success in a clinical setting: 
evidence and knowledge base, clinician adoption, and consistently-updated information.94 
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First, the highest quality of evidence, or knowledge, must be available at the time when it 
is most needed.  This requires a computable representation, or a clear organization of the 
information that is readily searchable and interpretable for the relevant clinicians or users of the 
information.  The information that the computable representation is built on should be based off 
the most updated evidence, and in cancer treatment and supportive care decision making, there is 
a large volume of literature to support this.65,95-98 
Second, CDS must have a high adoption rate and be effective in the delivery of the 
information.  This requires a clear and well-developed implementation strategy from CDS 
development to clinician and point-of-care delivery.  This pillar will need input from the 
healthcare provider as the end-user of a CDS system to ensure the system is usable and 
acceptable.  Building a CDS system, therefore, will require adequate stages of usability testing to 
ensure its success.85,99 
Finally, CDS must undergo consistent updates and improvement to ensure not only that 
the knowledge informing the CDS is updated but also that the strategy for implementing the 
CDS is also evaluated and updated.  This step initially requires an intensive process of manual 
review and updates of the available literature and evidence; however, a feedback system that 
continually learns from itself is possible and can result in an automated updating procedure.100,101 
A recent National Academy of Medicine meeting on CDS discussed its challenges and 
strategies to harness its potential in an increasingly-automated and technically-capable healthcare 
system.102 Focus should be on creating standards and incentives to use CDS, improving the 
evaluation of CDS, identification of clear measures of success, increasing engagement of 
stakeholders, specifically clinicians, in the design, implementation, and usability of CDS, and 
incorporating new knowledge, specifically patient-generated and patient-reported data into CDS 
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through integration and interoperability of electronic health record (EHR) systems.  These 
statements highlight the importance and capability that CDS should continue to have in our 
healthcare system.   
Electronic Health Record Data: Benefits and Challenges 
Changes to the US healthcare system, specifically the Affordable Care Act in 2008 and 
subsequently, Meaningful Use in 2010, increased the adoption of EHRs. As of 2016, 95% of 
hospitals eligible for the Medicare and Medicaid EHR Incentive Program were using health 
information technology to meet the required standards.18 This has led to an increasing capacity to 
improve the EHR infrastructure, streamline clinical information, and ultimately lead to 
improvements in healthcare through safer, higher-quality, and more efficient care.103 
As we move toward an era of rapid learning health systems in oncology care, the 
historical silos of single-institution data collection, storage, and management become 
increasingly important to exploit and adapt into an interoperable, transparent approach toward 
data collection methods. This system, as described by the American Society of Clinical 
Oncology, requires information-rich, patient-focused data, that can then be aggregated and 
synthesized into new evidence that will drive and transform cancer care delivery simultaneous to 
rigorous evaluation of patient- provider- and system-level outcomes.104  This iterative process 
necessitates ongoing forward movement and integration as new technology and methods become 
available. 
An integral component of this interoperability, implementation of the EHR, however, has 
been complex, and new challenges to care delivery have emerged. Meaningful Use 
acknowledges the need for calibrating the speed of EHR-adoption to the capacity of the end-
users, healthcare providers. Limitations remain, however, with EHR data not meeting newly-
CLINICAL DECISION MAKING IN CANCER CARE 
13 
developed data quality standards specifically relating to completeness, concordance, and 
plausibility.105 The limitations of EHR data inform a growing body of literature, and frameworks 
and desiderata have been developed to guide the requirements for high-quality, accurate EHR 
data, mostly based on common data element requirements.105,106 The goal of these standards is to 
achieve an EHR with patient information that are usable and optimized for interoperability. 
Patient Reported Outcome Measures 
A major limitation of EHR data relates to incompleteness, discordance, and heterogeneity 
of the data. Because historically, EHR data was developed for billing purposes, the current EHR 
systems have limited capabilities related to patient outcomes. Numerous patient-reported 
outcome measures (PROMs) have been developed and validated across patient populations,107,108 
and these measures are acceptable to patients and feasible to collect.  Importantly, routine 
screening of PROMs has been linked to improved symptoms, perhaps by bringing patient 
awareness and encouraging symptom self-management. Routine symptom screening using 
PROMs has in fact been linked to an improvement in survival in cancer patients.109,110 These 
measures, however, are primarily used in clinical research settings and may not be integrated into 
EHR systems. Barriers to implementation of PROMs include the variability of measures across 
institutions, time constraints, difficulty interpreting PROMs results, and liability concerns.111,112 
Facilitators to the use of PROMs in clinical settings have also been described, and integration of 
the PROMs with clinical practice guidelines to deliver a clinical decision support may be an 
enabler.113 EHR-integration of PROMs have been developed and tested,114 but are not routinely 
and consistently implemented nor are findings disseminated in the US healthcare system.  
PROMs can both improve patient symptom management but can also support the completeness, 
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concordance, and reduce heterogeneity in EHR data. Therefore, EHR-integration should be 
studied and developed further.115 
Importance of Standardized Data Elements 
The Observational Medical Outcomes Partnership (OMOP) has developed a Common 
Data Model (CDM) to transform data from multiple settings into a common format as well as 
map EHR data to standardized terminology.116 The OMOP-CDM is one example of a CDM that 
can support big-data healthcare analyses.  Standardized terminologies have been developed in 
many domains of healthcare, and the International Classification of Diseases, Tenth Revision, 
Clinical Modification (ICD-10-CM) and Systematized Nomenclature of Medicine - Clinical 
Terms (SNOMED-CT)117 are clinical terminologies used by health care providers for the 
electronic exchange of clinical health information. In addition to standardized terminologies, the 
Unified Medical Language System (UMLS)118 is a compendium of multiple vocabularies that 
utilizes the OMOP CDM in an effort to improve clinical data sharing and support 
interoperability.119 
With the concurrent increase in EHR use in the U.S. healthcare system, research has 
shifted to understand how standardized terminologies and informatics can drive new research.  
First, a system that follows the recommendations outlined by the data quality standards will be 
able to better utilize the clinical data to inform CDS systems and increase clinician awareness of 
and adherence to evidence-based guidelines.120,121 CDS requires a computable representation of 
the clinical data, and its success is largely dependent on unambiguous, complete, and correct 
documentation or data feeding the CDS system.94 
Second, because of the vast amount of information in the EHR, there is considerable 
effort being expended to optimize these data to support further knowledge generation and 
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research initiatives through secondary use of the data.105 Data quality standards should be used to 
guide the structure of a clinical data warehouse to better support retrospective research studies.  
By curating the data in a standardized way with common data elements, these data can be 
harnessed to assess existing evidence and determine if the findings are reproducible, adding rigor 
to our current evidence.122 With standardized documentation guidelines,  machine-readable 
algorithms can then reliably use the standardized EHR data to develop phenotypes and 
subsequent cohort studies.106 This methodology has been used in multiple settings; however, 
cancer-related symptom cohorts have not been studied.123 
Knowledge to Action: Conceptual framework 
The Knowledge to Action (KTA) framework124 is the guiding framework for this 
dissertation (Figure 1.1).  Knowledge translation, the key concept within this framework is one 
of many terms used in the field of implementation science and was defined in 2006 as ‘‘a 
dynamic and iterative process that includes the synthesis, dissemination, exchange and ethically 
sound application of knowledge to improve health, provide more effective health services and 
products and strengthen the healthcare system.’’125,126 The related framework that was published 
in 2011 describes two distinct components of knowledge translation: knowledge creation and the 
action cycle, or application of the knowledge.  This dissertation focuses both on the action cycle 
and the funnel of knowledge creation, acknowledging the fluidity of these two domains and the 
interrelatedness between them (Figure 1.2).  Although this dissertation does not propose to 
develop new clinical practice guidelines, each of the distinct studies identifies new areas of 
knowledge that inform the iteration of our action cycle and will provide a framework to evaluate 
outcomes in future studies.   
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The KTA framework is well-established in the fields of Implementation Science and 
Decision Making and so it is particularly well-suited to the proposed work.  This dissertation 
focuses on the identification of previously-established knowledge (evidence-based clinical 
practice guidelines), how this evidence can be implemented into clinical care (clinical decision 
support), the processes for translating this into clinical care (rate of guideline concordant care), 
and documentation within the electronic health record (completeness, concordance, and 
heterogeneity).   
Figure 1.1: Knowledge to Action Process Framework 
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This dissertation aims to address three gaps in clinical decision making in cancer care delivery. 
Specifically, the aims are to:  
Aim 1: Conduct a systematic review to identify clinical decision support (CDS) systems that 
have been used to assist in decision making for the therapeutic management of cancer 
Aim 1a: Determine the impact of the CDS on process- and patient-specific outcomes 
Aim 2: Determine the rate of guideline concordant care for the prevention of CINV in children, 
adolescents, and young adults with cancer receiving emetogenic chemotherapy 
Aim 2a: Identify predictors of guideline-consistent care for the prevention of CINV in 
children, adolescents, and young adults with cancer receiving emetogenic chemotherapy 
Aim 3: Examine the documentation of CINV in the EHR to describe the completeness, 
concordance, and heterogeneity of electronic health record documentation regarding 
chemotherapy-induced nausea and vomiting  
Aim 3b: Map the concept of CINV through UMLS to develop post-coordination 
expression and determine gaps in the concept definition to strengthen the data capture processes 
with SNOMED-CT crosswalk through UMLS 
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Chapter Two: Clinical decision support for therapeutic decision-making in cancer: A 
systematic review 
The study in Chapter Two addresses the first aim of the dissertation in a systematic 
review to identify clinical decision support (CDS) systems that have been used to assist in 
decision making for the therapeutic management of cancer, and to determine the process and 
patient-specific outcomes. 
Abstract 
Cancer management, including supportive care, is complex and requires availability and 
synthesis of published and patient-specific data to make appropriate therapeutic decisions. 
Clinical decision support (CDS) may be an effective implementation strategy to support complex 
decision making although it is unclear whether it improves provider outcomes, patient outcomes 
or both in cancer settings. We therefore conducted a systematic review to identify CDS that have 
been used to support therapeutic decision making in clinical cancer settings. Outcomes of interest 
included process outcomes or the effect of CDS on the clinician’s decision making, and the 
patient’s clinical response. Ten studies met inclusion criteria, with variability in the study design, 
setting, and intervention. Of the nine studies that measured process outcomes, four demonstrated 
significant improvement; and of the six studies that measured patient outcomes, four 
demonstrated significant improvement. All included studies utilized CDS that were informed by 
clinical practice guidelines while only three were integrated into the electronic health record. In 
conclusion, CDS to guide cancer therapeutic decision making is an understudied but promising 
area. Further research is needed. 
  




Forty percent of the US population will be diagnosed with cancer during their lifetime, 
and although the treatment and prognosis depends on the type and stage of cancer, the majority 
of cancer patients will undergo intensive treatment either for curative or palliative intent.1  
Further, provision of supportive care is important to maximize quality of life during treatment 
and to minimize late effects of therapy. Although treatment guidelines have been developed for 
many cancers, decision making for cancer management is complicated because many factors 
influence the best treatment plan for an individual patient.  First, the era of genomic testing and 
precision medicine has introduced a more complex treatment landscape due to the heterogeneity 
of cancer as a disease and provided insight into individual susceptibility to toxicities and late 
effects.2 Second, factors such as patient age, patient functional or clinical status, patient or 
provider preferences and values or patient insurance status may influence the prescribed 
treatment plan.3,4 Finally, our ability to predict, diagnose, and treat both cancer- and therapy-
related toxicities has improved greatly, and this sometimes allows for multiple options for an 
individual’s treatment plan.  For each clinical decision, providers are expected to have the most 
updated information to inform shared decision making with a patient and their family.127,128   
In addition to the complexities of clinically managing cancer, the burden of cancer 
continues to increase, primarily due to an aging population.20 The increasing burden of cancer 
and its costs impact upon clinical demands and overall care delivery.21 Health information 
technology (HIT) has frequently been cited as a main driver to any proposed solution. HIT is a 
key contributor to harnessing “big data” and allowing the healthcare system to learn from every 
patient, better predict the best treatment options and ultimately, deliver high quality care.129 With 
exponentially-increasing volumes of data becoming available through electronic health records 
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(EHR) and technology available to process and translate these data into usable predictive 
algorithms, a rapid learning health system for cancer care seems more tangible than ever.130  
Clinical decision support (CDS) is a HIT tool that processes patient-specific information 
through a previously-determined algorithm and provides clinicians with a data-driven 
recommendation to support clinician decision making at the point of care.102 Three concepts, or 
pillars, are required to give CDS the best chance of success in a clinical setting: a strong 
evidence and knowledge base, clinician adoption, and consistently-updated information.94 CDS 
tools or systems were first developed prior to the widespread use of technology in healthcare, 
and were usually paper-based and knowledge-driven rather than data driven. Although some 
early CDS systems demonstrated improvement in care delivery, commonly-cited barriers to CDS 
implementation included poor integration into clinical workflows and inability to constantly 
update the knowledge base in the CDS tool.131-133 Electronic and automated CDS were 
subsequently developed to overcome these barriers, and implementation of CDS has greater 
success if it is interoperable and integrated with the EHR.134  With suboptimal or lack of 
interoperability with the EHR, a CDS may not be perceived as useful and accepted into a busy 
clinical workflow. Ever-increasing HIT capabilities, however, allows novel approaches to 
address these barriers, and CDS is now considered a highly-valued component of improving care 
delivery across the healthcare system.102,135  Specifically in cancer, CDS has showed promise in 
cancer screening, prevention, diagnostic, and surgical or radiation oncology settings.136-141  
The benefits of CDS in settings where cancer is clinically managed, specifically to 
provide decision support for disease-directed therapy or supportive care management, however, 
are not well known. It is unclear whether CDS in these settings improves process outcomes, such 
as provider adherence to CDS recommendations, patient outcomes, such as reduction of 
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symptoms or satisfaction with care, or both.  Cancer-specific CDS in therapeutic settings should 
process the current evidence and provide relevant patient-specific knowledge and decision 
support in an understandable and usable format at the point of clinical care.  If integrated into a 
healthcare setting effectively, CDS may help to support appropriate, evidence-based care and 
ultimately improve patient outcomes in cancer management. The purpose of this systematic 
review is to: 1) describe clinical decision support systems that have been used in clinical cancer 
settings to guide therapeutic decision making, including supportive care management, and 2) 
measure the effect of CDS on care delivery process and patient outcomes.   
Methods 
Search strategy 
Four databases, PubMed, EmBase, OVID Medline and Institute of Electrical and 
Electronics Engineers (IEEE) Xplore, were searched to identify studies where electronic or 
automated CDS was tested to guide cancer therapeutic decision making, including supportive 
care management (see Appendix 1 for search strategy).  The search strategy was developed in 
consultation with an informationist at the primary author’s academic institution following the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.142  
This study was registered in Prospero (https://www.crd.york.ac.uk/PROSPERO/#recordDetails) 
and the eligibility criteria for included publications was defined a priori. Our search included 
studies from database inception through November 2018; we also conducted an updated search 
in April 2019 to identify any recent publications. For this study, we defined CDS broadly, and 
searched for terms including: CDS system, decision support system, decision aids and expert 
systems in our search terms. These terms were based off of prior publications.94,102,143 Inclusion 
criteria were 1) an electronic-based CDS; 2) studied prospectively in an oncology setting after 
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the diagnosis of cancer had already been made; 3) delivered CDS to a clinician; 4) the CDS 
provided therapeutic recommendations; 5) original research study; and 6) full text article was 
available.  Pilot studies were included as long the outcome, effect on care delivery process and/or 
patients, was reported. Studies were included regardless of publication date or language of 
publication. We excluded studies using a CDS to support cancer screening, cancer risk-
assessment, or cancer diagnosis as these clinical settings often differ from settings where cancer 
is treated, and symptoms are managed.  Similarly, we excluded studies where CDS guided 
surgical decision making, as this differs from therapeutic decision making. We excluded studies 
that were conducted retrospectively or post-hoc analyses of primary data.  We also excluded 
studies that only involved the patient and not clinician as this does not fit our a priori definition 
of clinical decision support but rather falls into symptom screening. Reference lists in the full-
text reviewed articles were examined, and relevant articles were included for review. 
Screening, Abstraction, Appraisal and Analysis: 
All eligible studies were entered into an EndNote database and then de-duplicated using 
the Bramer Method.144  All citations were then independently screened by two reviewers (MB, 
MM) by title and abstract using Covidence;145,146 reason for exclusion was documented. Any 
potentially relevant citations were then included in the full text review and the same procedures 
were repeated. Discrepancies were reviewed, and final consensus was achieved with a third 
reviewer (RS), when necessary.  
After full text review, variables of interest for the data synthesis were extracted from each 
included article by two reviewers (MB and MM).  These included: 1) disease(s) or symptom(s) 
being treated, 2) geographic location of study, 3) the proportion of clinicians who adhered to the 
CDS recommendation, 4) patient disease or symptom outcomes, 5) if the CDS recommendation 
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was based on a clinical practice guideline (CPG), 6) if the CDS was linked or integrated into the 
EHR. The Joanna Briggs Institute Critical Appraisal Checklist for Quasi-experimental Studies 
was used to determine the study quality of the included articles.147 Studies received 1 point for 
every component met, and total score indicated study quality with 1 – 3 low, 4 – 6 moderate, and 
7 – 9 high. Two reviewers (MB and MM) completed the checklist for each of the included 
studies, and any discrepancies were reviewed for consensus with a third reviewer (RS), when 
necessary.  
All studies were described qualitatively. The CDS were described by study type, 
geographic location, disease or symptom studied, CDS characteristics. The outcomes of interest 
were described and synthesized by effect on clinician and/or patient.  
Results 
Search Results 
Our initial literature search retrieved 951 citations; after de-duplication, 663 studies were 
included for title and abstract screening.  Reasons for excluding 565 are listed in Figure 2.1; most 
studies were excluded either because they described the technical CDS development process or 
they were clinical practice guidelines and not CDS studies. Ninety-eight studies were included in 
the full-text review, two of which were identified by reference searching, and ten unique, 
original studies met our inclusion criteria and were included in the final review.   
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Figure 2.1: PRISMA Flowchart for Literature Search 
 
 
Description of Studies 
Table 2.1 summarizes the characteristics and findings in each of the ten included studies. 
Five were prospective, pre-post designs comparing the effect of the CDS intervention to a prior 
period without the intervention. Four were single-arm interventional studies, one with multiple 
time points, 148 two utilizing historical controls as a comparison group, 149,150 and one without a 
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comparison group.151 Only one study was a randomized control trial (RCT).152 Three studies 
were conducted in the United States (US), and the remaining seven were conducted in Europe.  
Of the ten included studies, three provided decision support for cancer-directed treatment, 
specifically breast cancer, and the other seven for supportive care or symptom management. Of 
the latter seven, the most common symptom was cancer-related pain (n=3).  Notably, two of 
these seven studies approached cancer-related symptoms broadly, assessing and providing 
decision support on multiple symptoms 148,153 while one study focused on patient distress.154   
The CDS interventions themselves varied.  Three of the studies utilized the same CDS, 
OncoDoc, however, each study described a different study design or a different setting.149-151 The 
seven studies where the CDS was symptom-focused utilized distinct CDS systems.  Six of these 
interventions utilized patient-reported symptom information that fed the CDS algorithm to 
prompt and guide a clinician response.148,153-157  The type of CDS systems ranged from passive to 
active systems. The most passive systems included three studies utilizing the OncoDoc 
system149-151 and Van Erps’ study158 using the RESPOND system to manage chemotherapy-
induced anemia required manual entry of patient characteristics into the system that would then 
provide a recommendation. Four studies148,153,154,157 were intermediate in their automated 
responses, requiring patient-reported information that was processed into the system algorithm 
and then prompted the provider with a recommendation. Finally, two studies by Bertsche155 and 
Christ156 integrated EHR data into the algorithm that prompted a provider-facing decision 
recommendation. Three of the ten included studies154-156 had CDS interventions integrated into 
the EHR; one of these studies disclosed the EHR vendor as Epic Systems Corporation. All 
included studies reported that the CDS provided recommendations from a published clinical 
























Study Purpose Disease or 
symptom 











8 To test the impact of a 
CDSS on prescriber 
deviations from CDS 
recommendation for 
CPG-based pain 




1/NA/100 Yes Yes 
Bouaud 
(2001) 
4 To test the adherence of 
physician's treatment 
decision compared to 
that provided by a 
CDSS in breast cancer 
patients 
Breast cancer Single-arm pilot 1/13/127 Yes No 
Bouaud 
(2002) 
3 To test the adherence of 
physician's treatment 
decision (2nd site 
studied) compared to 
that provided by a 
CDSS in breast cancer 
patients 
Breast cancer Single-arm pilot 1/NR/NR Yes No 
Christ 
(2018) 
7 To test the impact of a 
CDSS on pharmacist 
deviations from CDS 
recommendation for 
CPG-based pain 




2/14/88 Yes Yes 
Cooley 
(2015) 
7 To test the feasibility of 
symptom screening 
linked to CDSS for 




Single-arm pilot 1/14/88 Yes No 
Li (2016) 8 To test the 
implementation of the 
Distress Assessment and 





1/16/196 Yes Yes 
Mooney 
(2017) 
8 To test the effect of 
routine symptom 
screening linked to 
CPG-based CDS for 
clinician follow-up on 




RCT 6/NR/358 Yes No 
Raj (2017) 9 To test the impact of a 
CDS for prescribers on 
patient-reported pain 
intensity levels and 
opioid prescribing 




1/NR/247 Yes No 
Seroussi 
(2001) 
8 To test the impact of a 
CDSS for breast 
oncologists when 
determining treatment 
plan for cancer patients 
Breast cancer Single-arm pilot 2/12/70 Yes No 
Van Erps 
(2010) 
6 To test the impact of an 
anemia-management 
CDSS on clinicians' 
management of cancer 
patients with anemia 
Anemia Pre-post 
interventional 
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Outcomes 
     Process outcomes. 
There was variability in the outcomes of the ten included studies (Table 2.2).  Although 
all of these studies included the clinician in the intervention as an inclusion requirement, one 
study did not measure process outcomes or an effect on the clinician’s behavior.153 Of nine 
studies that included process outcomes, five studies demonstrated an improvement in the 
clinician adhering to the CDS recommendation, four of which were statistically-significant (all 
with p<.001). Two studies did not show a significant difference, and the remaining two studies 
only provided an estimate of provider adherence. The effect varied and due to different process 
outcome measures, such as adherence to the recommendation (yes/no), provider intervention 
based on the CDS (yes/no), or deviation from CPG (multiple measures reported), summarizing 
the magnitude of benefit would not be appropriate. Table 1 provides further details about the 
individual process outcomes and effects.  
     Patient Specific Outcomes. 
Patient outcomes were measured in six of the ten included studies.  One study assessed 
mean hemoglobin levels,158 and the remaining five studies assessed patient-reported symptoms, 
or patient satisfaction (pain n=3, multiple symptoms n=1, distress assessment satisfaction 
n=1).148,153-155,157  Four of these six demonstrated an improvement in symptoms or in satisfaction 
with their care for the patients treated by CDS-informed providers (provided between-group 
differences with p<.05);153-155,158 and the other two showed no difference in groups. In the studies 
that showed improvement or benefit to the patient, the outcome measures varied, including pain 
scores, measured using different instruments, patient satisfaction scores, treatment impact scores, 
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and mean hemoglobin levels. A more in-depth summary of patient-specific benefit cannot be 
accurately described because of variability in outcome measures and definitions. Table 1 
provides further details about the patient outcomes and effects. None of the studies reported a 
worsening of symptoms or adverse effect related to the CDS.   
     Comparison by Outcome. 
Studies that measured both process outcomes and patient-specific outcome measures 
(n=5) varied in the agreement of the outcome effects. Three of these studies reported significant 
improvements in both process and patient outcomes, and all three CDS focused on symptom 
management: anemia, emotional distress, and pain.154,155,158 In addition, two studies, Bertsche et 
al and Li et al, were integrated into the EHR.154,155  
Table 2.2: Process and Patient O
utcom
es 
















Decreased number of 
patients with at least 1 
CPG deviation from 
84% to 14% (p<0.001) 
Yes Pain at rest by NVAS in 
intervention group 
decreased from 3.0 to 1.5 
compared to discharge 
(p<.01) and during activity 
decreased from 7.0 to 2.5 








61.42% vs 85.03% (p < 
0.001) 






N/A N/A No N/A 
Christ (2018) NCCN-CPG adherent 
pain regimen prescribed 
not changed (40% vs. 
46.9% p=0.97) 
No Patient-reported attainment 
of analgesia at 24h: 10.5% 



















Cooley (2015) Adherence of provider 
to CDS 
recommendation 
averaged 57% (95% CI: 
52 - 62%) 
N/A N/A Yes N/A 
Li (2016) Intervention for 
depression increased 
from 7% to 33% (p 
<.001) 
Yes Patients with intervention 
reported significantly 
greater satisfaction with 
emotional support (no 
further results available); 
patients with low income 
reported greater satisfaction 
with emotional support 
(8.67 v 5.75, p < .001) and 





N/A N/A Mean treatment impact for 
intervention group was 3.59 
severity points (p < 0.001), 
43% of the non-intervention 
group value. Intervention 
group had 3x fewer severe 
days (p<.001) than usual 
care. 10 of 11 measured 
symptoms were 
significantly lower for 



















CLINICAL DECISION MAKING IN CANCER CARE 
33 
Raj (2017) Proportion of patients 
starting a new opioid 
medication was not 
statistically different 
between groups (8.8% 
vs. 10.5%, p=0.69) 
No Mean pain intensity score 
were 3.6 and 3.3 between 
pre- and post-intervention 
groups (between group 
difference = 0.12, 95% CI: -




Site 1: Adherence 
96.6%, compliance 
64.28%; Site 2: 
Adherence 79%, 
Compliance 88%. 
(From Escher: increased 
compliance rate of 
decisions from 79% to 
93%) 
Yes N/A No N/A 
Van Erps 
(2010) 
Improvement in mean 
congruence scores to 
CPG between pre- and 
post-cohort (3.00 +-1.48 
compared to 8.18 +-
1.38, p<0.001) 
Yes Mean hemoglobin levels 
significantly increased in 
post cohort (0.80 +- 1.51 
compared to 1.90 +- 1.61, 
p<.01) and patients in post 
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Appraisal 
Table 2.1 presents the quality score of the studies that were included in this review using 
the Joanna Briggs Institute quality appraisal tool.159  Overall, the study quality was determined to 
be moderate to high with a mean score of 6.8 out of 9.  Most studies explicitly asked a research 
question, defined a comparison or control group, and stated the study period for each group. In 
addition, attrition was low. Studies published prior to 2009 scored lower than more recent 
publications.  
Discussion 
This systematic review of the literature provides a comprehensive summary of the 
existing studies that have been conducted utilizing CDS to guide therapeutic decision making in 
cancer settings.  We identified ten studies that suggest a trend toward both provider- and patient-
benefit. The small number of studies and variable outcome measures, however, are suggestive 
that this is an understudied area and the effect from CDS interventions on patient outcomes is 
unclear. Of the nine studies that measured process outcomes, five demonstrated an improvement; 
and of the six studies that measured patient-specific outcomes, four demonstrated improvement.  
The findings are discussed here in further detail.  
First, because only ten studies met our inclusion criteria, it appears that although there 
has been much emphasis on utilizing CDS to guide decision making in cancer,102  these systems 
have not yet been developed, tested, or published.  Our initial literature search identified many 
studies where CDS systems or tools were under development, with many technical aspects 
described in detail.  Therefore, it may be that these studies have not yet been developed into full, 
testable CDS or that other barriers have developed. Conversely, it is also possible that CDS have 
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been developed and are being utilized to guide therapeutic decision making in cancer, but they 
have not been studied or published. For example, a 2013 ASCO abstract reported on the 
development of a CancerLinQ CDS that would provide treatment decision support for breast 
cancer through an algorithm that made the ASCO guidelines machine readable and patient-
tailored through CancerLinQ, a rapid learning system for oncology.160  This suggests that 
therapeutic CDS have been developed and are potentially in use but not yet published.  
However, it is also possible that CDS relevant for certain diseases and symptoms have 
not yet been developed at all.  This may be due to two possible reasons. First, the heterogeneity 
of cancer and cancer symptoms may threaten the validity and reliability of a CDS even within a 
certain cancer setting. For example, the OncoDoc studies encountered many challenges 
incorporating the complexity of breast cancer treatment into its algorithm and required multiple 
iterative updates to the algorithm.  In addition, common barriers to technology-based approaches, 
such as cost, usability, and integration into workflow are well-established and may contribute to 
the lack of full CDS development in this area.102  
Another reason for the small number of studies that were identified may be related to the 
definition of CDS. We defined CDS as an electronic or automated tool or system that processes 
current evidence in the context of patient-specific information to provide knowledge and 
decision support to the clinician at the point of clinical care. We only included studies that 
provided decision support directly to a clinician and was then anticipated to be delivered to the 
patient.   
Our results differ from a recent systematic review of CDS systems in oncology 
practice.161 This review focused on CDS systems used to diagnose, treat, and manage cancer and 
identified 24 studies. In contrast, our review excluded the diagnostic period which accounts for 
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some differences in the identified studies. A major difference, however, relates to variability in 
definition of CDS. Our search strategies differed slightly, including our inclusion of the terms 
“expert system” and “decision aid.”94,102,143 We did not include terms “clinical pathways” or 
“online order entry” which may account for differences. Finally, we defined clinical decision 
support as a system or tool that provides patient-specific information and a recommendation for 
management to the provider. We excluded studies where patient-reported symptoms were 
captured and informed a prompt for follow-up by a clinician if it did not describe the decision 
recommended to the provider.  
There has recently been focus on automated patient-reported symptom screening linked 
to automated feedback directly to the patient. For example, Basch et al. have extensively studied 
a symptom tracking and reporting system that can link to automated feedback compared with 
nursing feedback through an email notification.162 Although these studies are promising from a 
symptom self-management approach, they do not meet our definition of CDS as the nursing 
feedback model did not provide decision support to guide the nursing-patient interaction. 
Importantly, however, this approach has demonstrated a significant improvement in overall 
survival for patients in the intervention arm, meaning that systematic screening of patient-
reported symptoms is associated with better patient outcomes.163 An earlier study by Sikorskii et 
al compared two multi-modal interventions for symptom management and found that both an 
automated intervention and a nurse-assisted intervention significantly reduced patient-reported 
symptoms (p < .01)164 Again, this intervention did not guide the decision making for the nurse.  
Therefore, in these and other similar studies165 it is unclear how or if high-quality feedback, such 
as guideline-informed care, is being provided to the clinician. Novel approaches to this 
challenge, such as those included in this systematic review by Li et al.,154 Cooley et al.,148 and 
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Mooney et al.153 suggest a broad symptom screening approach linked to evidence-based 
guideline recommendation may benefit patients and also be integrated into clinical workflows.  
We noted patterns between studies by the outcomes measured. Process outcomes in an 
implementation study of CDS serve as a surrogate outcome due to its proximity to the 
intervention and may be easier to directly measure.79 Although the goal of CDS systems is 
improving patient outcomes, these may be challenging to measure and changes in patient 
outcomes may have additional confounding factors that need to be considered. In this systematic 
review, five of the ten included studies measured both process and patient outcomes, and three of 
these reported significant improvement in both measures. In these three studies, one studied a 
CDS system to improve management of anemia,158, another to improve management of 
fatigue,154, and the third to improve pain management.155 Two of these, Li et al and Bertsche et 
al, were integrated into the EHR, and these same two also include patient-reported data that was 
integrated into the CDS algorithm. The remaining two studies by Raj et al and Christ et al, where 
both process and patient outcomes were measured, reported no significant improvement in either. 
Both studies used CDS interventions that provided pain-management decision support. 
Importantly, of the studies that measured patient outcomes (n=6), four reported significant 
improvement. The remaining two studies reported either no change or a non-significant trend 
toward improvement in the intervention group; no harm or worsening of symptoms was noted.  
Integration into workflows should include EHR-integration,93 however, only three of the 
identified studies included EHR integration as a component of the CDS.  EHR-integration, 
although it may be logistically challenging to implement, may improve some of the major 
workflow challenges that many have cited in clinical decision support.102,166  Kilsdonk et al. 
conducted a systematic review of barriers to implementing CPG-based CDS systems guided by 
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the human, organizational and technological factors framework.166 They found that along with 
utilizing a user-center design process and providing a recommendation at the exact time it is 
needed by the provider, the system should be integrated into the EHR or computerized provider 
order entry (CPOE) system to offer the best chance of success in providing useful information 
and improving patient outcomes.  Of the three EHR-integrated studies154-156 two were recently 
published, suggesting that future research will continue to explore this important component of 
CDS development. In addition, of these three that included EHR-integration, two showed 
improvement in process outcomes and patient-reported outcome measures. 154,155 
The geographic location of these studies is important to acknowledge.  Although CDS 
has been highlighted as an important area of research focus by the National Academy of 
Medicine and other US institutions,102 as well as specifically within cancer-specific 
organizations, only three of ten studies were conducted in the US.  This highlights an important 
gap which may be related to the complex healthcare system of the US and specific challenges of 
achieving the Meaningful Use goals of interoperability and health information standards, an 
important contributor to CDS success and sustainability.167,168    
Finally, all included studies reported using guidelines to inform the CDS 
recommendation.  This is important and promising, as current recommendations include 
provision of evidence-based care as a necessary component of CDS.134,135   
Limitations of this study 
There are some limitations to acknowledge within this systematic review.  Although we 
conducted our literature search in multiple databases, it is possible that we missed relevant 
studies that may be indexed elsewhere.  Similarly, grey literature was not included in the 
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literature search, which may have limited the inclusion of pilot studies, QI initiatives, or studies 
with negative findings.  
Another limitation is the lack of a singular definition for CDS. We defined CDS broadly 
in our search, including terms such as “expert system” and “decision aid”, however, we may 
have missed studies where CDS was the intervention and would have met our definition criteria, 
but the authors used other terms.  Although the informatics literature clearly states the 
technology-based definition, the clinical arena is sometimes ambiguous and includes a broad 
range and fast-paced integration of CPOE, order alerts, and other automated approaches to guide 
clinical decision making.  In addition, these initiatives may occur in clinical practice as quality 
improvement (QI) initiatives that inform iterative updates to EHR-workflow.  They may 
therefore not be published in a peer-reviewed journal or the clinical team leading the QI initiative 
may not include publication as part of their project.  This highlights the importance of rigorous 
science to inform implementation studies as well as dissemination as a critical component of 
implementing initiatives to improve care delivery.  Both dissemination and implementation 
should be encouraged across the landscape of quality improvement and assurance projects within 
healthcare settings.  
Finally, we excluded paper-based CDS as the purpose of this study is to understand how 
technology can improve care delivery. As we move toward learning healthcare systems and 
interoperability goals, it is imperative that strategies to improve clinical decision making, such as 
CDS, be developed in an electronic format. It is possible, however, that these excluded studies 
may have been electronically-based but did not explicitly state that they were using automation 
or electronic strategies.   
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Conclusion 
This study highlights the available evidence related to CDS that have been used in cancer 
settings to guide therapeutic decision making.  Few studies were identified, signifying an 
important gap that needs to be addressed in future research.  The studies that we identified had 
wide variability in their study setting, design and outcome measures. Encouragingly, all studies 
prompted a guideline-informed recommendation to the clinician, and more recent studies 
incorporated patient-reported information, supporting current initiatives toward standardized 
assessment of PROs and guideline-based interventions.169,170  Future research should focus on 
continuing to develop CDS that are usable, provide recommendations that are informed by CPGs 
to clinicians, are interoperable and integrated into the EHR, and ultimately impact upon and 
improve patient outcomes. 
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Chapter Three: Guideline Concordant Care for Prevention of Acute Chemotherapy-
Induced Nausea and Vomiting in Children, Adolescents, and Young Adults 
The study in Chapter Three addresses the second aim of the dissertation in a retrospective 
cohort study of patients less than 26 years of age who received emetogenic chemotherapy to 
determine the rate of guideline concordant care and to identify factors associated with receipt of 
guideline concordant care. 
Abstract 
Background: Chemotherapy-induced nausea and vomiting (CINV) is a common treatment-
related adverse effect in children, adolescents and young adults with cancer that impacts 
treatment adherence and quality of life. Prescribing guideline-recommended anti-emetics is an 
effective strategy to prevent CINV. However, the rate of guideline concordant care (GCC) is not 
well-understood.  
Methods: Using electronic health record data from 2016 through 2018, a retrospective single-
institution cohort study was conducted to investigate how often patients less than 26 years of age 
receive GCC to prevent CINV prior to administration of emetogenic chemotherapy. GCC was 
defined from the Pediatric Oncology Group of Ontario guideline for patients < 18 years and the 
American Society of Clinical Oncology guideline for those ≥ 18 years. Independent variables 
included: sex, age, insurance status, race, ethnicity, cancer type, chemotherapy regimen, clinical 
setting (adult or pediatric oncology), level of emetogenicity, and patient location (inpatient or 
outpatient). Predictors of GCC were determined using multiple logistic regression.  
Results: Of 180 eligible patients, 65 (36.1%) received GCC. In multivariable analysis, being 
treated in adult oncology (aOR: 14.3, CI95: 5.3 – 38.6), with a cisplatin-based regimen (aOR: 3.5, 
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CI95:1.4 – 9.0), solid tumor diagnosis (aOR: 2.2, CI95: 1.0 – 4.8), and commercial insurance 
(aOR: 2.4, CI95: 1.1 – 5.2) were associated with significantly higher likelihood of receiving 
GCC.  
Conclusions: Patient clinical and sociodemographic, as well as provider characteristics were all 
identified as being associated with receiving GCC for prevention of CINV in children, 
adolescents, and young adults receiving emetogenic chemotherapy. These findings can inform 
current efforts to optimize implementation strategies for supportive care guidelines by focusing 
on multi-level factors.  
Background 
Symptom management for children, adolescents and young adults with cancer is 
important; it reduces adverse effects of treatment, keeps treatment on schedule by reducing 
delays, and improves overall patient outcomes.171 Chemotherapy, a common treatment modality 
for cancer, often causes nausea and vomiting, which like other treatment-related adverse effects, 
can cause treatment delays and significantly reduce quality of life.172-174  It is also one of the 
most feared adverse effects of chemotherapy.26,38,172 It is therefore important to prevent and 
manage chemotherapy-induced nausea and vomiting (CINV), which can be achieved through the 
use of rigorously-developed evidence-based clinical practice guidelines.  
Provision of guideline concordant care (GCC) for the prevention of CINV requires 
knowledge about treatment-specific factors. Certain chemotherapeutic agents or combinations of 
chemotherapy have a higher emetogenic potential, and guidelines have been developed to 
classify the emetogenic potential of the most common chemotherapies.175,176 Guideline 
recommendations are based on these classifications and are available for pediatric and adult 
cancer patients.64,176-178  Although some patients may still experience symptoms of CINV with 
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appropriate prophylaxis, studies have shown that administering prophylactic regimens 
concordant with published guidelines can significantly reduce or control symptoms for patients 
who receive moderately or highly emetogenic chemotherapy.63,179,180  
Despite the availability of effective medications and rigorously-developed guidelines to 
help prevent and treat CINV specifically in pediatric oncology settings, there is wide variation in 
the provision of anti-emetic medications. One study found that 78% of sites self-reported a 
standardized approach to prophylaxis, however, only 41% reported that the approach was 
consistent with GCC.18 Some reasons for not providing GCC include lack of awareness of the 
guideline, concerns about drug interactions, specifically neurokinin-1 receptor blockers, and 
contraindications for dexamethasone use due to concomitant medication concerns or adverse 
effects of steroids.181-183 Furthermore, the guidelines may be viewed as less robust or trustworthy 
specifically in children, because the data for guideline development are often extrapolated, at 
least in part, from adult data.184,185 
The negative effects of this inconsistency are important, as children and adolescents with 
cancer may be undertreated or inappropriately prescribed medication leading to worse CINV 
symptoms than in older patients. Studies of adults with cancer have reported better CINV 
control, and a recent pooled synthesis of adult symptoms reporting a prevalence of 40% for 
nausea and 27%  for vomiting.186  In contrast, for children and adolescents, this number is 
frequently cited higher, especially chemotherapy-induced nausea. One study of school-aged 
children with cancer found that 80% of children with cancer reported nausea a week after 
chemotherapy and nearly half of parents reported nausea that caused significant bother.174 
vomiting prevalence ranged from 5 – 41% and notably, both symptoms are increasingly reported 
up to one week following chemotherapy administration.174,187 
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Symptom management, specifically prevention of CINV, is imperative to maximize 
patient outcomes in cancer treatment.  Though guidelines are available for children, adolescents, 
and young adults with cancer, it is not currently known how often they receive guideline-
recommended care and what factors are associated with receiving this care. Therefore, the 
purpose of this study was to describe the proportion of pediatric, adolescent, and young adult 
patients receiving highly-or moderately-emetogenic chemotherapy, to assess who 
prophylactically received guideline concordant antiemetic regimen to prevent acute CINV, and 
to identify potential predictors of guideline concordant antiemetic prophylaxis treatment. 
Methods 
Data Source 
A retrospective cohort study using the electronic health record (EHR) data of a large, 
urban hospital that includes a stand-alone children’s hospital, inpatient and outpatient cancer 
clinics all within an NCI-designated Comprehensive Cancer Center was conducted. This study 
was approved by the Institutional Review Board at Columbia University; a waiver of HIPAA 
authorization was granted (IRB-AAAR9461). 
Sample 
Subjects 26 years of age or younger who received chemotherapy classified by guidelines 
as either highly-emetogenic (HEC) or moderately-emetogenic (MEC)175,178 were included in the 
analysis (Appendix B). All chemotherapy classified by the 2011 antiemetic classification 
pediatric guideline175 as HEC or MEC were included because this guideline is broader in its 
inclusion of emetogenic chemotherapy. For patients > 18 years, the emetogenic classification of 
the chemotherapy regimen was confirmed as either HEC or MEC according to the American 
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Society of Clinical Oncology (ASCO) guideline. If it did not, they were excluded from the 
primary analysis.  
The Tripartite Request Assessment Committee (TRAC) of NewYork-Presbyterian 
Hospital, Columbia University Medical Center, and Weill Cornell Medical College has been 
established to share data across institutions for clinical care, operations, quality improvement, 
and research. Through this data request system, all patients were identified who received these 
chemotherapeutic agents between January 1, 2016 and December 31, 2018. Computerized 
provider order entry for all chemotherapy was the institutional mode of prescribing 
chemotherapy.  
Although all clinical settings where eligible patients were treated are within the same 
hospital system, the pediatric and adult oncology programs operate as distinct operations and 
utilize their own internal care pathways to provider cancer treatment and supportive care. Both 
pediatric and adult oncology divisions have developed recommendations for anti-emetic 
selection when ordering chemotherapy medications, however, the recommendations may or may 
not be based on guidelines and prescribers can opt-out of providing the recommended 
medications. The development process for these anti-emetic prescribing care pathways does not 
include a standardized methodology that is consistently and routinely updated.  
From this patient list, MB logged into the EHR of each patient to confirm eligibility and 
abstract the variables of interest for the dataset; the EHR domains of interest for the abstracted 
variables are listed in Appendix D. First, the date of the first chemotherapy encounter for each 
individual patient was confirmed. This was the episode of interest, and each patient was eligible 
to contribute one episode. Patients who had received prior chemotherapy at another institution or 
who previously received a regimen that was not classified as HEC or MEC were excluded. 
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Patients with a recurrence of their disease were included if the episode was the first 
chemotherapy administration for the recurrence. For patients who received an eligible 
combination of chemotherapy, the two chemotherapeutic agents had to be administered within 7 
days of each other.  
Antiemetics 
The medication administration record was accessed through the same procedure of 
institutional data request, and anti-emetic administered to the patient during the chemotherapy 
encounter were identified. The list of anti-emetics was developed from a review of CINV 
guidelines both for prevention of acute CINV, treatment of refractory CINV, and management of 
anticipatory CINV (Appendix C).62,178,188  Guideline-recommended anti-emetics were only 
requested if they were available through the hospital formulary during the study period.  
Anti-emetic administration was abstracted both from the automatically-generated list 
through the institutional request, as well as confirmatory EHR review.  In the EHR, all 
medication administration records were assessed to ensure any administration, even if the patient 
was in a different location from where the chemotherapy was administered, was captured.  For 
example, if a patient received ondansetron in the outpatient setting and was admitted for 
chemotherapy to the inpatient setting, this would be captured during the review and abstraction 
procedures.   
Each patient encounter was assessed to identify if they received the following classes of 
antiemetic: neurokinin-1 receptor blockers (NK1RAs), 5HT3 serotonin receptor antagonists 
(5HT3-blockers), and dexamethasone prior to the chemotherapy encounter. To be considered for 
evaluation of GCC, antiemetics needed to be prescribed and administered prior to the 
administration of chemotherapy. NKIRAs included fosaprepitant and aprepitant, which were the 
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NK1RAs on the hospital formulary, and 5-HT3 serotonin receptor antagonists included 
ondansetron, granisetron, and palonosetron.  Anti-emetics classified as “other” were also 
abstracted (Appendix C).  
Clinical and demographic characteristics 
Independent variables (e.g. clinical, system-level, and sociodemographic) were abstracted 
from the EHR as potential factors associated with receipt of guideline-recommended prevention 
of CINV.26,174,187,189 Clinical factors included: primary oncologic diagnosis (i.e. leukemia, 
lymphoma, solid tumor, or central nervous system (CNS) tumor), cancer recurrence, 
chemotherapy regimen, emetogenicity of chemotherapy regimen, and co-morbidities at the time 
of chemotherapy initiation. System-level factors included: location of chemotherapy 
administration (inpatient, outpatient), and clinical setting (pediatric, adult oncology).  
Sociodemographic characteristics included: age at the time of chemotherapy administration, 
categorized initially as 0 – 5 months, 6 months – 11 years, 12 – 17 years, 18 - < 26 years, and 
then dichotomized as 0 – 11 years and 12 – 26 years. Race and ethnicity were also collected, 
along with primary insurance status that was categorized as commercial/private insurance, 
governmental (i.e., Medicaid/Medicare), or uninsured/self-pay. Sociodemographic characteristics 
were abstracted from the patient demographic section within the EHR; if unavailable or not listed 
in that section of the EHR, MB reviewed the patient-completed intake forms that are scanned 
into the EHR and archived with other paper documents. In addition, insurance status at the time 
of chemotherapy encounter was confirmed by reviewing the social worker intake form, also 
located in the EHR.  




The primary outcome for this study was receipt of guideline concordant care for the 
prevention of acute CINV for patients receiving highly- or moderately-emetogenic 
chemotherapy. Patients were stratified by age, according to the published guideline 
recommendations for the prevention of acute CINV at the time of this study, one for children and 
the other for adults.  
For the patients < 18 years of age, GCC was defined using The Pediatric Oncology 
Group of Ontario guideline for prevention of acute CINV in children receiving chemotherapy; 
the guideline was updated in 2013 and again in 2017.61,64  This guideline, consistent with other 
guidelines for CINV prevention, recommends provision of a 5HT3-blocker, a corticosteroid, 
specifically dexamethasone, and a NK1RA to prevent CINV in children and adolescents 
receiving HEC.64  In the 2013 guideline, NK1RAs were not recommended for children under the 
age of 12 years due to limited pediatric data. The 2017 guideline, however, expanded the age 
limit anyone older than 6 months of age. For patients receiving MEC, this CPG recommends 
administration of a 5HT3-blocker and corticosteroid, specifically dexamethasone. For patients 
unable to receive dexamethasone, the recommendation supports using an alternative antiemetic, 
specifically metoclopramide, nabilone, or prochlorperazine.  
For young adults, defined in our study as 18 < 26 years, GCC was defined from the 
ASCO guideline, which similarly recommends triple therapy with a 5HT3 blocker, NK1RAs, 
and dexamethasone for patients receiving HEC.178 A recent update in 2017 added olanzapine to 
this recommendation.176,190  This medication has not yet been recommended for pediatric 
patients. For patients receiving MEC, the recommendation is identical to the pediatric 
recommendation: 5HT3-blocker and corticosteroid, specifically dexamethasone. Because both 
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the pediatric and adult guideline were updated in 2017, and our study includes this year, GCC 
was defined from the guideline previously published (e.g. for pediatric, 2013 and for adults, 
2011) given that the implementation of guidelines is often delayed.191 
Secondary Outcomes 
Our primary outcome was defined strictly from the guidelines which include 
dexamethasone as a component of GCC. However, in clinical practice there may be 
contraindications or hesitation to prescribe certain classes of antiemetics. To account for these 
differences, a secondary analysis was conducted to describe patients who receive dexamethasone 
and NK1RA separately.  
Statistical Analysis 
Descriptive statistics were computed to assess for the frequency of clinical, system-level, 
and sociodemographic characteristics as well as for the primary and secondary outcomes. Certain 
variables were collapsed into binary outcomes, specifically race (white, non-white), ethnicity 
(Hispanic, non-Hispanic), age (< 12 years, ≥ 12 years), cancer type (solid tumor, all other 
cancers), and chemotherapy regimen (cisplatin-based, non-cisplatin based) for bivariate and 
multivariable analyses. Associations between the predictors and primary outcome, guideline-
recommended anti-emetic regimen were calculated using Chi-square tests and logistic 
regression. Variables with a p-value < 0.1 in the bivariate analysis were included in the 
multivariable logistic regression model and independent variables with a p-value of < 0.05 were 
included in the final model. Odds ratios and 95% Wald confidence intervals were reported.  
Chi-square tests were used to assess for correlation between age and provider setting, and 
p-values were reported.  Testing for interaction was conducted using likelihood ratios (LR) test 
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between provider setting and insurance status. All analyses were conducted using SAS version 
9.4 (SAS Institute, Cary, NC). 
Results 
Through the institutional data pull from the TRAC system, 295 patients were identified; 
After review of each of these charts, 115 were excluded due to not having cancer (n= 47), 
chemotherapy dosing not qualifying as HEC or MEC (n= 18), receiving prior chemotherapy at 
another institution (n= 25), and duplicate patient records (n=20).  Table 3.1 describes the 
characteristics of the 180 patients included in our final sample. A slight majority (54%) were 
male, 41% had commercial insurance at the time of treatment, 61% were white and 63% were 
non-Hispanic. The largest age groups were the 6m-7y (37%) and young adults >17y (40%). Most 
were seen by pediatric oncology providers (73%), in the inpatient setting (73%). The most 
common cancers were solid tumor (41%) and leukemia (24%), and most received HEC (71%) 
with 19% of the sample receiving cisplatin-based regimens. Most patients were undergoing their 
first treatment (85%) and were not being treated for relapsed disease. Seventy-four percent 
(n=133) did not have any co-morbid conditions at the time of chemotherapy administration. Of 
those who did, asthma (n=8), post-organ transplantation (n=8), and congenital syndromes (n=10) 
were the most common conditions.  
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Table 3.1: Summary of Sample Characteristics (n=180) 
Independent Variable N (%) 
Sex  
Male 98 (54.4%) 
Female 82 (45.6%) 
Insurance (primary)  
Medicaid/Medicare  103 (57.2%) 
Commercial 73 (40.6%) 
Self-pay/non-insured 4 (2.2%) 
Age group  
0 – 5M 5 (2.8%) 
6M – 11Y 67 (37.2%) 
12Y – 17Y 36 (20%) 
18Y < 26Y 72 (40%) 
Race  
White 110 (61.1%) 
Black 32 (17.8%) 
Asian 13 (7.2%) 
Unknown 25 (13.9%) 
Ethnicity  
Non-Hispanic 114 (63.3%) 
Hispanic 64 (35.6%) 
Unknown 2 (1.1%) 
Location  
Inpatient 132 (73.3%) 
Outpatient 48 (26.7%) 
Provider setting  
Pediatric Oncology 132 (73.3%) 
Adult Oncology 48 (26.7%) 
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Table 3.1: Summary of Sample 
Characteristics (n=180) (cont’d) 
Emetogenicity 
Highly-emetogenic (HEC) 127 (70.6%) 
Moderately-emetogenic (MEC) 53 (29.4%) 
Chemotherapy type 
Carboplatin 12 (6.7%) 
Cisplatin 34 (18.9%) 
Dacarbazine 12 (6.7%) 
Dactinomycin 21 (11.7%) 
Other HEC  48 (26.7%) 
MEC 53 (29.4%) 
Cancer type 
Solid tumor 73 (40.6%) 
Lymphoma 48 (26.7%) 
CNS 16 (8.9%) 
Leukemia 43 (23.9%) 
Cancer status 
First occurrence 153 (85%) 
Relapse 27 (15%) 
Of the 180 patients, 36% received age-appropriate, guideline concordant anti-emetics 
prior to the administration of chemotherapy. In the bivariate analysis (table 3.2) five independent 
variables were found to be significantly associated with receiving GCC (table 3.3). Race was not 
included due to the large number of patients with “unknown” status (14%). In the multivariable 
model, four variables: provider type, primary insurance, tumor type, and chemotherapy regimen, 
were included and remained significant at the 5% level (table 3). Age group was not included in 
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the multivariable analysis as it was highly correlated with provider type (Chi-square: 43.6, 
p<.0001). 
Table 3.2: Bivariate Analysis of Independent Variables and Outcome: Guideline Concordant 
Care Received 





Total 65 115  
Sex   .90 
Male 35 63  
Female 30 52  
Insurance (primary)   .02* 
Non-commercial 31 76  
Commercial 34 39  
Age group: young vs. old >12y   .03* 
0 – 11Y 19 53  
12Y < 26Y 46 62  
Race   .01** 
White 31 79  
Non-White 34 36  
Ethnicity   .50 
Non-Hispanic 39 75  
Hispanic 26 40  
Location   .20 
Inpatient 44 88  
Outpatient 21 27  
Provider setting   <.0001* 
Pediatric Oncology 29 103  
Adult Oncology 36 12  
Emetogenicity   .33 
Highly-emetogenic (HEC) 43 84  
Moderately-emetogenic (MEC) 22 31  
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Table 3.2: Bivariate Analysis of Independent Variables and Outcome: 
Guideline Concordant Care Received (cont.) 
Chemotherapy type   <.001* 
Cisplatin based therapy 21 13  
Non-Cisplatin based therapy 44 102  
Cancer type: solid vs. not   .007* 
Solid tumor 35 38  
All others 30 77  
Cancer status   .91 
First occurrence 10 17  
Relapse 55 98  
* Significant at the 5% level, included in multivariable logistic regression 
** Excluded from multivariable regression due to 14% “unknown” status 
 
Table 3.3: Results of Multivariable Logistic Regression 
Independent variable Bivariate Analysis Reduced Model 
Provider setting OR: 14.3 (5.3 – 38.6, 
p<.0001) 
aOR 10.9 (4.8 – 
25.0, p<.0001) 
Age OR: 1.6 (.64 – 4.0, 
p=.31) 
* 
Primary Insurance OR: 2.4 (1.1 – 5.2, 
p=.02) 
aOR 2.3 (1.1 – 4.9, 
p=.03) 
Solid tumor vs. other 
cancer 
OR: 2.2 (1.0 – 4.8, 
p=.04) 




OR: 3.5 (1.4 – 9.0, 
p=.01) 
aOR: 3.6 (1.4 – 
9.3, p<.01) 
*Excluded from reduced model 
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Sensitivity Analysis and Interactions 
 A sensitivity analysis was conducted to explore the relationship between emetogenicity 
and other independent variables. Bivariate analysis between emetogenicity and all independent 
variables revealed associations with provider setting and age. Pediatric oncology patients were 
more likely to receive highly-emetogenic chemotherapy than adult oncology patients (p=.07), 
and younger patients < 18 years were more likely to receive highly-emetogenic chemotherapy 
than patients ≥ 18 years (p = .08). All other associations were not significant at the (p < .10) 
level.  
In addition, we assessed for interaction between provider setting and insurance status 
using the LR test. We ran two models, the reduced and full. In the full model -2L Log L: 
intercept=124.289, Intercept and covariates = 103.605; and in the reduced: -2L log L: intercept 
124.289, intercept and cov = 105.368. Since the test statistic (G2) = 105.368 – 103.605 is < the 
critical value for X2 df = 2, .05 = 5.991. Therefore, we do not have sufficient evidence to support 
that insurance status modified the association between provider type and GCC at the .05 level of 
significance. 
Secondary Outcomes: Antiemetics by Drug Classification 
 Ninety-eight percent (n=177) of the total sample had received a 5HT3-blocker; 44% 
(n=80) received dexamethasone, and 26% (n=46) received a NK1RA. Receipt of dexamethasone 
was reported by tumor type, acknowledging the clinical limitation of administering steroids to 
patients with brain tumor, leukemia, and lymphoma, because they often receive steroids as a 
component of anti-tumor treatment. A sub-group analysis on patients with solid tumors, therefore 
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with no overt contraindication or concomitant concerns for dexamethasone, identified 62% 
(45/73) of patients received dexamethasone.  
Receipt of NK1RA for patients receiving HEC was also examined by age group. None of 
the youngest age group and 10% of the 7m – 11y group received a NK1RA. In older patients for 
whom the guideline recommends NK1RAs, of those 12 – 17y of age, 26% received NK1RAs 
whereas 64% of the oldest group ≥ 18 years received NK1RAs, consistent with GCC. Overall, 
49% (35/71) of patients 12 years and older received a NK1RA.  Finally, 35% (n=64) of the 
sample had received additional anti-emetics prior to their chemotherapy. There was wide variety 
in the medication(s) given, and the most commonly prescribed was lorazepam (n=52). 
Discussion 
 Our study found that in a cohort of patients ≤ 26 years of age receiving emetogenic 
chemotherapy, 36% received guideline concordant anti-emetic prophylaxis.  To our knowledge, 
this is the first study to describe the rate of GCC in a pediatric and young adult patient 
population. This is an important finding that highlights both the importance of guideline-based 
supportive care in children, adolescents, and young adults with cancer but also the challenges in 
prescribing both to younger patients and for specific types of cancers.  
 Our study finding of a low rate of GCC is consistent with the limited literature describing 
GCC in pediatric oncology symptom management. A multi-institutional survey conducted 
through the Children’s Oncology Group found that less than half of the 36 participating 
institutions followed institution-specific guidelines, with only 28% following the CPG endorsed 
by the Children’s Oncology Group.18 Our results provides further knowledge about the patient-
level rate of guideline concordant care. In addition, our study found that patients treated in adult 
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oncology were significantly more likely to receive GCC. Current initiatives, such as the ongoing 
trial through the Children’s Oncology Group (NCT02847130), aim to understand both the 
barriers and facilitators to implementing supportive care guidelines in pediatric cancer settings 
and to improve how well these guidelines are understood by healthcare providers. Our study 
supports the need to conduct this and future research in this area to increase guideline uptake in 
pediatric cancer settings.  
 The evidence-base for the development of pediatric-specific guidelines, is often based, at 
least in part, on data from studies in adults or in rigidly-defined populations.184 In CINV studies, 
for example, much of the efficacy data for antiemetics comes from specific populations, such as 
those receiving cisplatin-based therapy.178 Our study found that patients receiving cisplatin-based 
regimens were significantly more likely to receive GCC, suggesting that awareness about the 
need for optimized prophylaxis is heightened in this population, perhaps related to the evidence-
base from which the data comes. Specifically, in our study only 14% of patients receiving 
dactinomycin and 14% of patients receiving combination chemotherapy classified as HEC, 
received GCC. Future interventions that increase awareness of the classification of 
chemotherapies are therefore warranted.  
In addition, because much of the evidence-base for guideline development comes from 
data in adults, it is important to consider the distribution of cancer in adults compared with 
children and adolescents. Adults have a higher prevalence of solid tumors, and prescribing 
dexamethasone does not come with the same challenges as in the more prevalent pediatric 
cancers, leukemia and CNS tumors.192 Specific issues with prescribing dexamethasone include 
concomitant dosing of additional corticosteroids, such as prednisone which is commonly part of 
the anti-tumor regimen, or the side effect profile of corticosteroids, including behavioral, 
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infectious, and bone-related toxicities.193-195 Importantly, leukemia is the most common 
childhood cancer, and this highlights some of the challenging is providing appropriate antiemetic 
control to younger patients. Guideline-recommended interventions may not, or cannot in some 
cases, be adhered to due to protocol or clinical restrictions. 
Similarly, there are known pharmacokinetic interactions of NK1RAs with specific 
chemotherapies and other commonly-used medications in cancer management.196 These include 
clinically significant pharmacologic interactions between cyclophosphamide IV, and 28% of the 
patients included in this study received this as a component of their regimen. In addition, adverse 
events related to a drug interaction between a NK1RA and other medications were described, 
including anthracyclines and ifosfamide, and 28% of the patients included in this study received 
one of these chemotherapeutic drugs. NK1RA are an important part of CINV management; 
however, it is important to consider their side effect profile and interactions with commonly-used 
chemotherapy.  
The 2013 pediatric guideline recommends that patients who cannot receive 
dexamethasone or an NK1RA as recommended should receive secondary medications as 
prophylaxis, and the 2017 guideline similarly recommends palonosetron, a specific 5HT3-
blocker, that has demonstrated increased efficacy in pediatric settings. These are limited optimal 
prevention strategies for younger patients, and some of these medications having significant side 
effects such as extrapyramidal effects and sedation.64 In fact, a negligible number (n=13) of 
patients in this study received one of the three recommended medications for patients who are 
unable to receive dexamethasone. This supports the need for a more robust evidence-base of 
pediatric-specific guidelines as well as rigorous testing of newly-approved medications 
specifically in pediatric patients.184,197  
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Recent federal regulations highlight the need for increased drug development and testing 
in children and adolescents. Prior to 1997, few drugs were approved for use in children; since the 
Food and Drug Administration (FDA) Modernization Act, pediatric efficacy and safety data has 
been encouraged and sometimes required in drug development and approvals.198 Exemptions 
have been allowed especially for cancer drugs due to the relative rare status of pediatric cancer. 
A recent update to the regulation, however, will remove the exemption and require pediatric 
testing regardless. Recent statements from the FDA acknowledge and state support for improved 
pharmacologic interventions with supporting evidence base for children.199 
Our study also identified disparities in the delivery of GCC. Patients with primary 
commercial insurance were significantly more likely to receive GCC (p=.02).  This disparity in 
CINV management should be explored across multiple institutions to better understand and 
validate this finding. A previous study of adult breast cancer patients described disparities in 
receipt of GCC related to social determinants, reporting that black women were 11% less likely 
to be prescribed NK1Ras compared with white women.189  However, in our study, over 70% of 
the patients were inpatient for their chemotherapy, and in general, individual medications are not 
charged but are bundled. It is possible, therefore, that this disparity is a proxy for other 
sociodemographic disparities that were not identified in this single-institution study. Larger 
studies in multiple settings are therefore needed to further explore disparities in delivering GCC 
for CINV prevention and management.  
Multiple factors significantly associated with receiving GCC were identified. Multi-level 
implementation strategies have been cited in the literature as an effective mechanism to address 
patient-, provider-, and system-level barriers to guideline implementation. Specifically through 
the Expert Recommendations for Implementing Change (ERIC),76 strategies such as clinical 
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decision support integrated into the electronic health record, audit and feedback, approaches to 
change organizational climate, and collaborations may be useful to improve cancer care delivery 
across multiple settings.200 These approaches can help to identify patient-level clinical and 
sociodemographic factors and provide guideline-based decision support. Other strategies, such as 
enhanced education and discussions to increase awareness of and develop quality improvement 
strategies that clinicians feel comfortable adopting and implementing may also be effective and 
should be explored further.201 Certainly, a multi-level approach to improve guideline-based care 
is needed to address cancer symptom management.  
Strengths and Limitations 
This study has some strengths and limitations worth discussing. First, this is a single-
institution study, thus limiting the generalizability of the findings. However, because of the 
patient-level data from the EHR, the reliability of these data is strong, which is a common 
challenge of larger, insurance database studies.  
Another limitation is our inability to appropriately assess for disparities, specifically by 
race as previously cited in the literature due to 14% of patients having “unknown” status in the 
EHR. Capturing patient-level sociodemographic data is an ongoing challenge for many 
healthcare systems, and the Institute of Medicine and other governmental agencies continues to 
support the importance of these data in healthcare disparities research, quality improvement 
initiatives and quality measures.202,203 These and local initiatives should be encouraged to 
improve the accuracy of data reporting. 
Finally, due to our limited sample size, relationships between other factors and GCC may 
not have been identified with the potential for a type 2 error. Significant relationships between 
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multiple factors and GCC, however, were identified, suggesting that these relationships are 
internally valid. This work would be strengthened by broadening the study both to multiple 
settings or institutions and increasing the sample size.  
Future implications 
The findings from this study contribute important knowledge to the evidence base of 
supportive care guideline implementation and adherence in pediatric, adolescent, and young 
adult settings.  Data such as this can be used as a benchmark to measure initiatives to increase 
provision of GCC.  Currently, ongoing initiatives at local and national levels aim to understand 
barriers to providing GCC to these patients and to develop interventions to improve rates of 
GCC. Our study supports the need for both provider- and patient-level interventions.  
Policy implications are also important to acknowledge; children and adolescents are frequently 
underrepresented in drug safety data. The U.S Food and Drug Association acknowledges this as 
a limitation and incentivizes pharmaceutical companies to include a pediatric-specific component 
of new drug applications;199,204 however, there is still clearly a paucity of pediatric-specific data 
that is generalizable across multiple clinical and sociodemographic settings.205 Similar to prior 
publications about the importance of guideline development in pediatric oncology, increasing the 
evidence base to develop these guidelines should continue to be a focus. 
Conclusion 
In summary, in this retrospective cohort study of children, adolescent, and young adults 
with cancer and receiving emetogenic chemotherapy, an overall low rate of GCC was found. 
Factors associated with receiving GCC include provider specialty, chemotherapy regimen, type 
of insurance, and type of cancer diagnosis. Future implementation strategies should focus on 
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these factors to improve rates of GCC. In addition, further research is needed to define 
alternatives for antiemetic regimens when certain classes, specifically NK1RAs and 
dexamethasone, cannot be given. Federal and pharmaceutical funding should support develop of 
pediatric medications.  
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Chapter Four: Completeness, Concordance, and Heterogeneity of Documentation of 
Chemotherapy-Induced Nausea and Vomiting in Children and Young Adults with Cancer 
The study in Chapter Four addresses the third aim of the dissertation in a mixed-methods 
study to describe the completeness, concordance, and heterogeneity of the EHR documentation 
about CINV in patients less than 26 years of age who received highly-emetogenic chemotherapy. 
Abstract 
Objective: To describe the completeness, concordance, and heterogeneity of the electronic 
health record (EHR) documentation of chemotherapy-induced nausea and vomiting (CINV), to 
map the concept of CINV using clinical terminologies, and to develop a post-coordination 
expression.  
Methods: A mixed-methods study was conducted to examine the EHR of children, adolescents, 
and young adults who recently received highly-emetogenic chemotherapy. In Phase I, we 
described how often CINV was assessed and reported by prescribers and registered nurses (RNs) 
and the concordance by clinician type and by ICD-10 codes. In Phase 2, we utilized the terms 
identified in Phase I and from validated CINV tools to map the concept of CINV through 
SNOMED-CT and then UMLS and develop a post-coordinated approach for phenotyping 
patients with CINV.   
Results: 127 patients’ EHRs were reviewed, and of these a total of 870 patient notes were 
reviewed. Documentation of CINV assessment by prescriber was present in 75% of patients, and 
by RNs was present in 58% of patients. Of the 60 encounters where both prescriber and RN 
documented an assessment, 72% agreed on the presence/absence of CINV. We mapped CINV 
first through SNOMED-CT and subsequently through UMLS to incorporate other terminologies, 
mainly ICD-10 and Rx—NORM. Post-coordinated expression of CINV was applied to the 
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documentation from the EHR and partially identified patients’ CINV status 85% for prescriber 
and 100% for RN documentation, and completely identified patients’ CINV status 21% for 
prescriber and 38% for RN documentation.  
Discussion and Conclusion: Although most patients receiving highly-emetogenic chemotherapy 
have a documented assessment of CINV, most patients had incomplete and discordant 
documentation of CINV, most commonly, temporality and severity were not documented. In 
addition, heterogeneity of documentation location was noted.  Mapping the terms through UMLS 
informed post-coordination expression of CINV to improve capture of the presence or absence of 
CINV but did not improve the completeness of the documentation, specifically related to severity 
and temporality of the symptom. 
Background 
Electronic Health Record Data 
Electronic health records (EHRs) are now ubiquitous in healthcare, and as of 2017, 94% 
of hospitals eligible for the Medicare and Medicaid EHR Incentive Program used their EHR data 
to measure hospital processes and inform clinical practice.206 There are ever-increasing amounts 
of data available through EHR records, and methods to interpret and utilize these data for 
secondary use of these data has been widely explored.207 EHR data quality is a well-described 
challenge to secondary use, and common challenges include lack of completeness, correctness, 
concordance, plausibility, and currency of the data.208 EHR data quality reported in the literature 
varies widely depending on the clinical concept of interest as well as healthcare system- or 
institutional-level variability.  
Two dimensions of data quality, completeness and concordance of EHR data are 
commonly cited as challenges when researchers, clinicians, and administrators use these data to 
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characterize patients.209 For the purpose of this study, completeness is defined as patient-level 
documentation that is present and available in the EHR, and concordance is defined as the 
agreement between elements, observations or values  that are documented in the EHR.208 
Incomplete data occurs when data is not documented or only partially-documented. Incomplete 
data may be related to the pertinent negatives that are not routinely documented in clinical care. 
However, one cannot assume that because the data is not present, clinical observations were not 
noted by the clinician who is documenting and/or experienced by the patient.210 Another reason 
for incomplete data may be due to a lack of integration for patient-reported outcomes or 
preferences in the EHR system. If available and integrated into the EHR, these data can increase 
the completeness of data and therefore, utility of patient-level data. Currently, these data are not 
routinely integrated into the EHR system.211   
Discordance in EHR data may occur when multiple providers document differing 
observations in the EHR or when factors, such as the timing of a clinical event or the clinician 
workflow, cause a provider to document one observation in one location of the EHR and a 
different observation in another location.212 In addition, both incomplete and discordant data can 
also be due to errors in documentation. Understanding the completeness and concordance of data 
in the EHR provides a baseline assessment of data quality that is needed prior to harnessing EHR 
data for clinical research purposes.105  
Another challenge with EHR data is heterogeneity, often related to the multitude of data 
types that may be available in the EHR. For example, a clinical data warehouse may access data 
from multiple systems and locations with the EHR, and then need to integrate structured and 
unstructured data into an understandable format for future use to measure patient and process 
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outcomes.213 Heterogeneity within EHR data causes challenges when clinicians, administrators, 
and researchers want to identify and analyze non-structured data and free text from the EHR.  
Strategies to assess, utilize, and interpret EHR data have been described, and historically 
required manual review by clinical experts and knowledge engineers, a time-consuming and 
costly process.214 Recently, more efficient methods have been developed and refined including 
automated methods to phenotype, or characterize, common patient characteristics from EHR 
data.215 Phenotyping can identify patients with common comorbidities or risk factors who may 
benefit from interventions to improve patient outcomes.216-218 Phenotyping can be conceptualized 
from two aspects, top-down knowledge engineering and bottom-up learning from the data. 
Phenotyping methods often utilize prior knowledge engineering and concurrently integrate new 
knowledge from structured and unstructured EHR data. To phenotype a common characteristic 
from EHR data, however, it is important to assess and understand the data quality. 
Phenotyping algorithms, or the pathway to identify the cohort of interest, commonly 
depend on controlled terminologies. Controlled terminologies have been developed to allow for 
meaningful representation of data using symbols; they support “the capture, storage, 
manipulation, and retrieval” of information in a way that preserves the original meaning of the 
data.219  Multiple taxonomies, or clinical terminologies, exist to cover the breadth and depth of 
health-related information that is found in health insurance databases, electronic health records, 
genomic, and other health-specific databases.220  
The Systematized Nomenclature of Medicine -- Clinical Terms (SNOMED-CT), a 
commonly-used, standardized healthcare terminology is considered the most comprehensive in 
the world.221 Implementation of SNOMED-CT into EHR systems supports consistent, 
comprehensive representation of relevant clinical information which is necessary for reusing 
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EHR data in a single health system as well as supporting health information exchanges across 
systems. SNOMED-CT has numerous pre-coordinated expressions available that provide 
relevant contextual information about multiple health-related terms; figure 4.2 shows the 
diagram for the pre-coordinated term “chemotherapy-induced nausea vomiting.” In the absence 
of a pre-coordinated expression, however, a strength of SNOMED-CT is the ability to “post-
coordinate” expressions by building terms together with modifiers and qualifiers. For example, 
in the absence of the pre-coordinated expression readily available in the EHR documentation, a 
post-coordinated expression can identify patients who have pre-defined terms, also called atoms, 
available in the clinical documentation to better identify patients with a specific characteristic. 
SNOMED-CT can be mapped to other common terminologies, such as the 1) International 
Classification of Diseases (ICD)-10 codes,222 a terminology used for reporting morbidity and 
mortality data to National Center for Health Statistics and the Centers for Medicare and 
Medicaid Services and for billing in healthcare systems; and 2) RxNorm, a standardized 
nomenclature for clinical drugs.223  
The Unified Medical Language System (UMLS)221 is a comprehensive system that brings 
together many of these terminologies (e.g. SNOMED-CT, RxNorm, ICD-10) to enable 
interoperability across systems. One specific UMLS knowledge source, the Metathesaurus, links 
terms and codes from multiple vocabularies and terminologies. UMLS is a helpful resource to 
organize and link terminologies, integrate them into algorithms, and develop patient-specific 
phenotypes or cohorts to identify associated predictors and mediators of disease. Ultimately, 
UMLS may be used to support development of phenotyping algorithms and prospective, 
predictive modelling interventions, such as clinical decision support (CDS) systems.100,101,130  
UMLS is also useful to leverage existing data and conduct retrospective studies.  
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The predictive capabilities as well as the ability to harness already-existing EHR data to 
understand patient outcomes are important strengths of phenotyping EHR data, and data-driven 
phenotyping is a well-described methodology used to identify common diseases, such as chronic 
kidney disease, diabetes, or atrial fibrillation.216,217,224 To our knowledge, however, this approach 
has not been used to develop cancer-related symptom phenotypes. 
Cancer Symptom Management 
Symptom management is an integral component of high-quality cancer care, and 
appropriate identification and management of symptoms can improve patient-reported quality of 
life and reduce adverse effects of both disease and cancer-related treatment.171 One of the most 
common treatment-related symptoms is chemotherapy-induced nausea and vomiting (CINV), 
affecting up to 80% of cancer patients.38 Evidence-based guidelines have been rigorously 
developed both to classify the emetogenicity of chemotherapy and to provide recommendations 
to prevent and treat CINV.61,175,176,225,226 These guidelines offer treatment-, age-, and timing-
specific recommendations that can be incorporated into a care pathway or algorithm. Despite the 
evidence that supports these guidelines, they are not always followed in clinical practice.18,227 
There is wide variety on providing guideline-consistent care, and adherence to guidelines may be 
lower in pediatric settings.18 Barriers to guideline implementation have been described and are 
often classified by patient-specific, provider-specific, and system-level factors.84  In CINV 
prevention and management, barriers include difficulty appropriately identifying patients at risk 
for CINV, lack of systematic symptom screening for at-risk patients, and outdated or incomplete 
knowledge of the most up-to-date guideline, especially in children and adolescents as the 
guideline recommendations are often age-specific.    
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Significance and Purpose 
The importance of CINV as a symptom,228 the challenges in providing high-quality 
treatment to prevent and manage it,18 and the contributing nuances associated with prescribing 
medication to children and adolescents argue for a better method to appropriately identify 
patients at-risk for and currently with CINV in real-time and for secondary data use. Therefore, 
phenotyping methods may offer a mode to identify at-risk or symptomatic patients, a needed 
component to support guideline implementation, such as CDS.102,105,208  First, a comprehensive 
understanding of the data quality is necessary, and the data quality of CINV documentation has 
not yet been described.  In response to this gap, the purpose of this study was to conduct a 
mixed-method study to describe the completeness, concordance, and heterogeneity of CINV 
documentation in an EHR system, and to develop a data-driven approach to improve 
identification of patients with CINV using clinical terminologies.   
Materials and Methods 
Phase 1: Documentation of CINV 
     Data source 
A retrospective cohort study was conducted using data from the EHR of pediatric and 
young adult oncology patients at a large, urban hospital that includes a stand-alone children’s 
hospital, inpatient and outpatient cancer clinics all within an NCI-designated Comprehensive 
Cancer Center. This study was approved by the Institutional Review Board at Columbia 
University; a waiver of informed consent was granted because it was determined that the study 
involved no more than minimal risk to the subjects and could not practically be carried out 
without the waiver (IRB-AAAR9461). 
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     Sample 
Subjects 26 years of age or younger who received one of the drugs, or drug combinations, 
classified by published guidelines for children and adults as highly-emetogenic chemotherapy 
(HEC)175,178 were included in the analysis. This sample is a subset of the cohort, which included 
patients receiving both highly- and moderately-emetogenic chemotherapy and was described in 
detail in the previous study for this dissertation (Chapter Three, p.58).  
     Procedures 
The EHR system was entered and the patient-specific medical record number for each 
patient who had received HEC in the cohort previously described in Chapter Three was inputted 
into the system. This allowed entry into the patient-level record, specifically the AllScripts 
application, which provides complete access to all clinical documentation. Multiple domains of 
the EHR were explored and documentation was abstracted from the follow-up encounter 
following administration of HEC.  
The follow-up encounter was defined as the clinical encounter following the 
administration of highly-emetogenic chemotherapy, and the specific definition was determined 
by the location where the patient received HEC. For patients who received HEC in the inpatient 
setting, this was defined as the documented assessments during the acute phase of chemotherapy, 
up to 24-hours following completion of chemotherapy for the first chemotherapy cycle or 
through discharge from the hospital, whichever came first. All clinical documentation was 
assessed following the date of first administration of chemotherapy through the acute phase by 
the prescribers, defined in this study as physicians or nurse practitioners, and registered nurses 
(RN).  
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For patients who received HEC in the outpatient setting, the follow-up encounter was 
defined as the subsequent clinical encounter where they were seen at the hospital or clinic after 
receiving the first chemotherapy cycle with HEC. The location of this visit (outpatient vs. 
inpatient) was confirmed through EHR review. If the patient was admitted to the inpatient unit 
following outpatient receipt of HEC, the follow-up encounter was defined as the first inpatient 
encounter documented in the EHR.  
All documentation by prescribers and RNs relating to CINV in the EHR for the first 
follow-up encounter was assessed. For prescribers, all notes during chemotherapy administration 
through the acute phase were assessed for documentation about nausea or vomiting, and the 
history of present illness section was directly abstracted from the chart into the dataset as free 
text. The RN documentation was similarly assessed for any documentation about CINV. Types 
of documentation that was abstracted included the chemotherapy administration notes, all 
symptom assessments, flowsheets, and nursing discharge summaries, educational, or 
miscellaneous notes. The number of documents assessed per patient was recorded.  
From each follow-up encounter, documentation of CINV assessment by prescribers 
and/or RN was abstracted, and if documented, the documentation was assessed for the presence 
or absence of CINV. The symptom was coded as assessed if there was a specific comment about 
the presence or absence of nausea, vomiting, or similar terms.  CINV was coded as present if 
there was any mention in text or discrete structured datapoint that acknowledged the presence of 
nausea, vomiting, retching, or if there was a documented emesis event on the RN flowsheet. If 
CINV was present, any text about the severity, temporality, or any other relevant descriptors of 
the symptom was also abstracted into the dataset. Administration of chemotherapy at the follow-
up encounter was also abstracted from the medication administration record of the EHR.  Finally, 
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three types of billing codes, specifically the ICD-10 codes,222 from the encounter were 
abstracted: primary oncologic diagnosis, encounter for or encounter following chemotherapy, 
and CINV-related codes. The EHR sections of interest are described in Appendix D. This list 
was informed by a pilot project conducted previously (abstract accepted, AMIA Symposium 
2019).  
     Outcome measures 
From each follow-up encounter, the following outcomes were described: the 
completeness of the EHR documentation defined as 1) if CINV was assessed in the 
documentation by prescriber; 2) if CINV was assessed in the documentation by RN; 3) if CINV 
was documented as present by prescriber; 4) if CINV was documented as present by RN; the 
concordance of the EHR defined as 1) if assessments by both the prescriber and the RN were 
available, were the two assessments in agreement; and 2) if the ICD-10 codes were in agreement 
with the data abstracted from the prescriber’s documentation within the EHR for a) primary 
oncologic diagnosis b) visit for chemotherapeutic encounter and c) presence of CINV symptoms; 
and the heterogeneity of the EHR documentation was defined as the number of notes and 
locations within the EHR that were assessed to identify the prior outcomes.  
     Data Analysis 
Following data abstraction from the EHR, quantitative variables were coded as binary or 
categorical. For these variables, descriptive statistics were computed to provide with frequency 
tables. A bivariate analysis was then conducted using Chi-square to assess the association 
between the clinical and demographic variables and the outcomes of interest (i.e. CINV 
assessment, CINV present as reported by prescriber and RN, ICD-10 codes, and agreement by 
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provider type and ICD-10 codes). For associations from the bivariate analysis with a p-value < 
.05, simple logistic regression was conducted to further describe associations between predictors 
and outcomes; odds ratios were calculated.  The proportion of patients for whom the assessment 
for CINV was concordant between prescriber and RN notes, as well between prescriber 
documentation and ICD-10 codes for oncologic diagnosis, visit for chemotherapy, and CINV 
were all calculated.  All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, 
NC). 
Phase 2: SNOMED-CT Overlay and Mapping through UMLS 
After the Phase I study was conducted from the patient-EHR, the UMLS Metathesaurus 
Browser,221 which includes SNOMED-CT, 50 was explored to identify the related terms and 
concepts for CINV. Both browsers were utilized because SNOMED-CT is a commonly-used 
terminology for processing healthcare data (e.g. billing, phenotyping); and UMLS provides a 
link with other terminologies that may be necessary to comprehensively phenotype CINV. In the 
SNOMED-CT web browser, the string “Chemotherapy-induced nausea vomiting” and segments 
of this string were entered to identify any related terms. The pre-coordinated concept was then 
explored in UMLS Metathesaurus to identify other related terminologies for the concept. All 
concept unique identifiers (CUI), lexical or term unique identifiers (LUI), and atom unique 
identifiers (AUI), listed in UMLS and classified under nausea, vomiting, or chemotherapy-
induced nausea (and/or) vomiting were identified. The ICD-10 diagnosis codes abstracted during 
Phase I, specifically for primary oncologic diagnosis, antineoplastic encounter, and follow-up 
from antineoplastic encounter were also included in our mapping. UMLS was also referenced to 
identify codes for specific chemotherapy drugs through RxNorm, which links to many drug 
vocabularies commonly used in pharmacy management.223  
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Qualifiers and modifiers were also included in the mapping process; these were identified 
both through the UMLS search as well as the clinical documentation abstracted in Phase I and 
were categorized as post-coordination expressions. The Interactive MetaMap,229 a freely-
available indexing tool that has natural language processing capabilities, was explored to 
determine the utility of natural language processing specifically to determine negation of 
symptoms. Finally, two validated instruments for CINV assessment, the pediatric nausea 
assessment scale (PeNAT) for pediatric assessment and the MASCC Antiemesis Tool (MAT) for 
adult assessment were utilized to ensure all terms relevant to CINV assessment were included in 
our concept mapping.230,231 In an iterative process, a diagram of all related terms and concepts of 
CINV mapped through UMLS that would reflect complete assessment and documentation of 
CINV was developed.  
After fully mapping the concept, each patient-level encounter with a documented CINV 
assessment was analyzed to determine if the concept mapping would identify the patient as either 
having or not having CINV and, if available, the qualifiers and modifiers to describe the severity 
and temporality of CINV. Each documented assessment of CINV was classified as follows: 1) 
able to determine CINV status with a pre-coordinated expression available in the documentation, 
2) able to determine CINV status using the post-coordinated expression or 3) able to partially 
determine CINV status using the post-coordinated expression. For assessments where the 
presence or absence of CINV was documented, but another domain (e.g. temporality, severity), 
was not, these would be counted as partially identified using a post-coordinated expression. The 
frequency of pre- and post-coordination expressions to identify both the prescriber and RN 
documented assessments were described. Two researchers (MB and MA) independently coded 
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20% of all cases to ensure reliability, and any disagreements were resolved through discussion 
and if necessary, through a third-reviewer.  
Results 
Phase 1 
     EHR assessment of CINV. 
The inclusion criteria yielded 127 subjects in the retrospective cohort receiving highly-
emetogenic chemotherapy over a 3-year period. The characteristics of the sample are described 
in Table 4.1. One patient did not follow-up with a prescriber, and therefore only had RN 
documentation available. In addition, all except for one patient who was admitted following 
outpatient receipt of HEC, were in the same location as the HEC administration.  
Table 4.1: Summary of Sample Characteristics (n=127) 
N (%) 
Sex 
Male 68 (53.5%) 
Female 59 (46.5%) 
Insurance (primary) 
Commercial 52 (40.9%) 
Non-commercial 75 (59.1%) 
Age group 
0 – 5M 5 (3.9%) 
6M – 11Y 51 (40.2%) 
12Y – 17Y 27 (21.3%) 
18Y < 26Y 44 (34.7%) 
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Table 4.1: Summary of Sample 
Characteristics (n=127) (cont.) 
Race  
White 80 (63%) 
Not White 47 (37%) 
Ethnicity  
Non-Hispanic 85 (66.9%) 
Hispanic or other 42 (33.1%) 
Location  
Inpatient 92 (72.4%) 
Outpatient 35 (27.6%) 
Provider location  
Pediatric 98 (77.2%) 
Adult 29 (22.8%) 
Chemo type  
Cisplatin 34 (26.8%) 
Non-cisplatin  93 (73.2%) 
Cancer type  
Solid tumor 62 (48.8%) 
Lymphoma 38 (29.9%) 
CNS 15 (11.8%) 
Leukemia 12 (9.5%) 
Cancer status  
First occurrence 115 (90.6%) 
Relapse 12 (9.4%) 
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     Completeness of documentation. 
Prescriber assessment of CINV was documented in the EHR for 95 patients (75.4%). 
Factors associated with an increased likelihood of documenting CINV assessment included 
chemotherapy regimen and sex. Receiving a cisplatin-based therapy as the HEC regimen was 
significantly associated with having CINV assessment documented in the EHR (OR: 4.3, CI95: 
1.2 – 15.3). Male sex was also significantly associated with a lower odds of having CINV 
assessment documented compared with female sex (OR: 0.37, CI95: 0.15 - 0.88). Of 95 patients 
where an assessment was documented, CINV was present in 63 (66%); none of the predictors 
were found to be significantly associated with a documented presence of CINV.  
Of the 127 patients who had follow-up encounters with the RN, nursing assessment of 
CINV was documented in 72 patients (57%). Patient location during the follow-up encounter 
was significantly associated with RN documented assessment with those seen in the inpatient 
setting less likely to have a documented CINV assessment (OR: 0.04, CI95: 0.01 - 0.32). Of the 
72 patients for whom assessment was documented, 40 (56%) reported CINV as present; none of 
the patient- or encounter-specific variables were significantly associated with the documented 
presence of CINV. Twenty-five (63%) of those where CINV was documented was present were 
from inpatient structured flowsheets reporting the number of emesis episode(s); in these 
documented assessments, no further descriptors about the symptom were available in the 
documentation. 
     Concordance of documentation. 
Fifty-nine (46%) of all patients had a CINV assessment documented by both prescriber 
and RN; of these, 40 (68%) reported concordant assessments. Reasons for discordance varied but 
included recent report of CINV by prescriber and an assessment of no symptoms by RN marked 
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in a discrete structured checklist. Another type of discordance was due to an emesis episode 
documented by the RN with the prescriber reporting no symptoms. Table 4.2 provides examples 
of concordant and discordant assessments. Of the 40 concordant assessments, 32 (80%) agreed 
that CINV was present, and the remaining eight agreed that CINV was not present (Figure 4.1).  
Table 4.2: Examples of Discordant Documentation 
Prescriber documentation RN documentation 
No acute events overnight. Afebrile, no cough 
or runny nose. No problems with constipation 
or diarrhea. No nausea/vomiting. Tolerating 
chemotherapy well so far. Appetite ok. No 
bleeding. No pain. 
Patient vomited immediately after first attempt of 
prednisone dosing at 1700. Second dose of 
prednisone attempted at 1800 with medication 
crushed in ice cream. Patient did not tolerate and 
vomited. Mother present at bedside.  
No significant events overnight.  Afebrile.  No 
vomiting or diarrhea.  Constipation - no BM 
since Tuesday.  Appetite has been good.  No 
cough, runny nose, or other URI Sx's.  No 
reports of hematuria.  No other bleeding signs 
or Sx's reported.  No problems with pain.  No 
other problems or concerns reported 
*NO TEXT, CHECKED 1 EPISODE EMESIS
Started chemo 3/21, w/delayed vomiting yest 
and today. Seemed to have jaw pain, but 
teething. Seems fussy changing position. 
Remains afeb. 
*NO TEXT, CHECKED NO SYMPTOMS
C/o nausea, but no vomiting. Is still eating and 
drinking. 
Nausea: None and Zofran given ATC at home. 
Vomiting: None.  
Of the 126 patients who had follow-up encounters with a prescriber, twenty (15.9%) 
included an ICD-10 code for CINV compared to the 61 reported in the EHR documentation. Of 
the 95 patients where CINV was assessed by the prescriber, 47 (49.5%) of the documented 
assessments agreed with the ICD-10 code for that encounter. Of the 20 patients where the ICD-
10 code for CINV was present, 17 (85%) of these agreed with the provider assessment. ICD-10 
codes for chemotherapy encounters were correctly documented in 81 patients (63.8%), whereas 
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ICD-10 codes for primary oncologic diagnosis were correctly documented in 100% of the 
patients.  
Figure 4.1: Completeness and Concordance of CINV Documentation by Provider Type 
     Heterogeneity of documentation. 
In total, 390 prescriber notes and 480 RN notes were reviewed. Prescriber documentation 
was primarily abstracted from the oncology prescriber note(s) during the acute phase of 
chemotherapy (up to 24-hours following completion of all chemotherapy). However, this class of 
notes included six distinctly-named documents depending on provider setting (adult, pediatric 
oncology) and location (inpatient, outpatient). The HPI, an unstructured data domain, was the 
primary source for documentation abstraction.  
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Nursing documentation was abstracted from six unique locations including flowsheets, 
shift assessments, and various nursing-specific notes. The flowsheets and shift assessments were 
all structured data capture, with an option to include free-text; the nursing notes were a 
combination of structured and unstructured data. The locations, note titles, and EHR domains are 
provided in Appendix D.  
Phase 2 
     Concept mapping of CINV. 
Through an iterative approach, the concept map for the components of CINV 
documentation that would be needed to evaluate data quality and to accurately and completely 
identify patients with CINV from EHR data using a data-driven approach was developed. First, 
in the SNOMED-CT browser, the concept “chemotherapy-induced nausea and vomiting” was 
entered and identified a pre-coordinated expression, concept ID 18846006 (Figure 4.2). The 
diagram for this concept provided additional information, specifically that nausea and vomiting 
“is a disorder” that is “associated with chemotherapy” and the “finding site is upper 
gastrointestinal tract structure.” The parent term did not have any related children.  
Figure 4.2: SNOMED-CT Concept Diagram for CINV232 
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Each related concept ID from SNOMED-CT was entered into the UMLS Metathesaurus 
Browser using the “term search” and identified the SNOMED concept, C0401160, semantically 
categorized as a “Pathologic Function, T046”. Within this concept, 10 associated atom unique 
identifiers were identified, most of which were from either the SNOMED-CT terminology and 
the Consumer Health Vocabulary, a terminology designed to complement the medical 
terminologies to aid the needs of the consumer. These terms, or atoms, were reviewed and were 
consistent with the CINV-related terms identified during Phase I of this study. Twenty-nine 
related contexts were also identified, 13 of which were within the SNOMED-CT terminology 
and determined to be most relevant (other contexts included non-English language use of the 
concept, and “sibling” contexts such as travel-related nausea vomiting which we determined to 
be outside the scope of our investigation). Of these 13 contexts, all were located under “clinical 
finding.” This means that information about CINV would most likely be found in clinical 
documentation, such as those examined during Phase I. With this information, the first iteration 
of the concept mapping was developed which identifies the presence or absence of CINV.  
Our next iteration started with a review of the text found in the EHR documentation and 
the two validated CINV assessment tools to identify any outstanding information that was 
needed to completely describe CINV. The main findings from this iteration revealed the need for 
qualifiers and modifiers to convey the temporality, frequency, and severity or bother of the 
symptom. These domains sometimes were found in the EHR documentation when CINV was 
documented as present, however they were more clearly found in the validated instruments. To 
capture temporality, multiple concepts were identified, however “time of onset” (C0449244), 
was determined to be most accurate. In addition, clarification about the timing in cases where the 
symptom was previously present but now resolved was also important (e.g. “nausea and 
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vomiting after last cycle, now resolved”).  The concepts for “Present” (C0150312) and “Absent” 
(C0332197) were also included in the mapping. After mapping temporality, frequency was 
explored and “Symptom frequency” (C0436350) was identified as the most related term. Finally, 
severity was explored. Although the documentation infrequently captured this characteristic, the 
CINV assessment tools, specifically related to nausea, ask about how bothersome or severe the 
symptom is for the subject.  For vomiting, this may also be captured by frequency. To assess 
severity, SNOMED-CT has a specific concept “Nausea and vomiting status” (C1319170) with 
symptom “Nausea and vomiting severity.” Because this is very specific, two severity modifiers, 
“Moderate” (C0205081) and “Severe” (C0205082) were included.  
At this iteration, the full concept of CINV was mapped; however, identifying these 
patients prospectively was unlikely to be successful using this framework. Therefore, additional 
diagnostic and medication terms were explored: first, ICD-10 codes for primary oncologic 
diagnosis (C00-C97; C0006826), “Encounter due to Chemotherapy session for neoplasm” 
(C0476658) and/or “Follow-up examination after chemotherapy for malignant neoplasm” 
(C0476668); and second, RxNorm because this terminology can be used to identify patients 
receiving certain drugs in the EHR, such as highly-emetogenic chemotherapy drugs. The ICD-10 
code for CINV was not included given its poor sensitivity and specificity in Phase I. Figure 4.3 
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Finally, although MetaMap was able to identify the concept of CINV from the text if it 
was a positive assessment (“patient complaining of nausea and vomiting”), it did not capture 
negation in any of the patient examples. The “NegEx” option theoretically should enable the 
algorithm to identify negative concepts. This was not true in this setting.  In addition, the nursing 
symptom assessments were often discrete, structured documentation (e.g. Nausea √; or Emesis = 
1). If the nurse did not explicitly write one of the atoms associated with CINV in the free text 
section, it would not identify the concept as “nausea” or “vomiting.” Therefore, MetaMap and 
natural language processing methods were not included in the mapping. 
     Assessing the data quality of EHR documentation utilizing CINV concept map 
Of the 95 patients who had a prescriber assessment of CINV documented, a related term 
from the concept map was identified in the EHR documentation. For 25 patients (26%), a 
precoordinated concept for CINV status was documented in the EHR. Most (n=16, 64%) of these 
patients had a negative prescriber assessment of CINV. Applying the post-coordinated 
expression to the patient documentation allowed us to identify the status of six patients (6%). In 
the 72 patients (76%), applying the post-coordinated expression was partially successful in 
identifying the CINV status. This means that some component of CINV was captured. In fact, in 
most patients (n=55, 76%), post-coordinated approach identified two or less domains of CINV 
assessment. Severity, noted through terms such as “severe nausea” or “mild nausea and 
vomiting,” was the most commonly-missing CINV domain and only available in nine (9%) to 
apply the post-coordination approach.  
Of the 72 patients who had a RN assessment of CINV documented, 28 (37.8%) had a 
clear precoordinated expression available in the documentation. Only one of the 28 assessments 
were positive for CINV. Applying the post-coordinated expression was partially successful in the 
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remaining 45 patients CINV status; this approach identified either the presence/absence of the 
symptom but did not provide severity or temporality. Most of the RN documentation of CINV 
was through structured data capture that did not capture the modifiers and qualifiers, specifically 
severity and temporality.  
Discussion 
This mixed-methods study describes the documentation of CINV assessment in the EHR 
and developed a path to improve the complete and concordant capture of CINV using available 
terminologies. The results of Phase 1 demonstrate that documentation in the EHR of CINV is 
frequently incomplete and varies by provider type; 75% of prescribers and 58% of RNs 
documented an assessment in a cohort of children, adolescents, and young adults receiving HEC. 
Also, when CINV assessment was documented, the rate of concordance by provider type was 
72%. Phase 2 of this study utilized both the EHR documentation and validated instruments to 
assess CINV, and the researcher found that the EHR structure is suboptimal and does not 
currently support the relevant terms and concepts needed to accurately and completely describe 
the symptom.  
CINV should always be assessed, particularly when a patient is receiving HEC. An 
ongoing challenge with EHR documentation is incomplete data,215 and one cannot assume that 
data that is not present is the same as a negative outcome. Missing data is generally attributed to 
a mistake or more commonly, an assumption of pertinent negative findings; however, the 
researcher purposefully chose a cohort of patients receiving HEC and the highest risk CINV.233 
The proportion of missing data in this cohort, in contrast to the known prevalence of CINV, 
suggests that other factors may be at least partly responsible. Consideration of incomplete 
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documentation includes workflow challenges,234 and it is likely that CINV was assessed by many 
of the clinicians; however it was not documented.  
In cases where the EHR demonstrated the presence of CINV, the incompleteness of 
documentation was notable. Few assessments fully expounded on the temporality, severity, and 
frequency of the symptom, although validated assessments include these components and 
guideline recommendations vary depending on them. The incompleteness noted in this study 
may be related to lack of a validated assessment tool capturing the data and integrated into the 
EHR in addition to workflow challenges.  Complete documentation of CINV symptoms by 
clinicians may not be feasible to implement and sustain in a busy clinical workflow. The concept 
mapping, developed both from text in the EHR and from validated instruments, provides a 
pathway toward integration of patient-reported outcome measures into the assessment and 
documentation workflow.163,235,236 The effect of this integration is not well-studied; however, 
these findings support its potential utility to completely capture symptoms. Ultimately, 
incorporating and studying the utility of patient-reported outcome measures into the EHR is 
important. Although providers assess symptoms during clinic or inpatient visits, complete 
symptomatology is not well-captured in this EHR system. 
Interestingly, two potential predictors for CINV documentation emerged with prescribers 
significantly more likely to document CINV assessment on females (p=.03) and patients 
receiving cisplatin-based regimens (p=.02). These are important findings given that historically, 
female sex has been considered a risk factor for nausea and vomiting in general, but also 
specifically for CINV,237,238 and cisplatin is one of the oldest chemotherapies that was known to 
cause CINV.239 A recent study developing a prediction tool to identify at-risk adult cancer 
patients for CINV, however, did not find that sex was a significant predictor of CINV.240 
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Similarly, although cisplatin has historically been the gold-standard for studying CINV 
pathophysiology and pharmacologic interventions,239,241 all chemotherapy classified as HEC 
have a >90% likelihood of causing CINV within 24 hours of administration if not otherwise 
treated.  Therefore, both associations suggest that, as often acknowledged in data quality, there 
are biases that exist relating to EHR documentation.242 Bias to assess certain patients for CINV 
supports the importance of systematic symptom screening in high-risk patients regardless of non-
validated patient factors and initiatives to increase awareness by clinicians about the importance 
of documenting clinical assessments.  
Applying the post-coordinated expression that was developed during concept mapping 
correctly identified the presence or absence of ≥ 85% of the patients who had a documented 
assessment of CINV by prescriber and 100% of those with RN documentation. The majority of 
these were partial assessments, which is related to incomplete data, specifically about the 
severity and temporality of the symptom. This is also important because available terminologies 
do not support complete documentation of cancer-related symptoms and required post-
coordinated efforts. Further expansion of existing terminologies should include focus on cancer-
related symptoms.  
Although using a post-coordination approach did not completely describe CINV 
symptoms, the ability to identify the presence or absence of symptoms is important. Similar to 
other studies using post-coordinated approaches to phenotype patient-level data, our study 
suggests that this may a feasible approach to leverage the already-existing EHR data for 
decision-support systems, billing purposes, and retrospective data capture.105,243 This study 
provides the first step toward identifying patients at risk for CINV simply by utilizing the ICD-
10 and RxNorm terminologies, and to identify patients with CINV using the full UMLS mapping 
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and post-coordinated approach. The ability to identify “at-risk” and “diseased” patients are both 
important to phenotype patients and develop interventions, such as CDS. These systems can then 
provide decision support for early identification of patients who should receive prevention of or 
treatment for CINV. CDS may be an effective guideline implementation tool, especially when it 
is integrated into the workflow, such as through EHR integration or supported by patient-
reported data.  
This study provides the foundational knowledge for EHR documentation to completely 
and accurately describe a cancer-related symptom. This study, however, was conducted manually 
and has not been automated into a programmable algorithm. The researcher chose this approach 
to increase the granularity and improve the internal validity of the findings; however, similar to 
historical phenotyping,214 the manual approach will not be sustainable across multiple settings 
and automated development will be needed to move toward predictive modelling and CDS 
development. 
Strengths and Limitations 
This study has some notable strengths and limitations. To our knowledge this is the first 
mixed-method study examining the data quality, specifically the completeness, concordance, and 
heterogeneity of CINV assessment and documentation. Our approach includes both knowledge 
engineering by leveraging existing data and terminology structures, and bottom-up learning from 
new data in the EHR. This comprehensive and innovative methodology to analyze a common 
cancer symptom contributes new knowledge to the field and can inform the next generation of 
EHR systems.  
It is important to acknowledge the limited generalizability of this study due to using data 
from a single-institution and a single EHR system. The findings, specifically the completeness 
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assessment, may vary widely by hospital or clinical setting as well as by EHR system.  Future 
studies should examine differences across institutions and/or EHR systems to test the validity of 
this approach in multiple settings. Because CINV is a universal cancer symptom, however, the 
researcher anticipates that the concept mapping will largely be generalizable across sites that 
utilize EHR systems.   
Another limitation of this study is the focus on three domains of data quality: 
completeness, concordance, and heterogeneity. There are other domains of data quality that are 
associated with challenges utilizing EHR data for secondary use, such as correctness, 
plausibility, and currency of data.210 However, for the first two domains, correctness and 
plausibility, without another validation source, such as paper charts or patient-reported measures 
for comparison, cannot be fully described. To assess currency of data, the timing of data entry or 
data logs are often reviewed, and access to EHR audit records was not feasible to obtain for this 
study. We did, however, include three dimensions to strengthen our assessment of the data 
quality of CINV documentation in the EHR. 
Conclusion 
In summary, this study is a mixed-method, two-phase study that characterizes the data 
quality of CINV assessment in the EHR to develop a comprehensive data-driven approach to 
capture this symptom in the next generation of EHRs. The findings highlight the gaps in 
capturing symptoms in modern terminologies such as SNOMED-CT, a weakness that should be 
studied further to move toward phenotyping and predictive modelling of cancer symptoms. 
Notably, this study highlights the importance of incorporating patient-reported information into 
the EHR to improve completeness and concordance of symptom documentation, both in real-
CLINICAL DECISION MAKING IN CANCER CARE 
90 
time for future decision support systems, as well as in population-based studies to understand 
and measure cancer symptoms across multiple settings.  
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Chapter Five: Discussion and Conclusion 
The goal of this dissertation is to provide a better understanding of clinician decision 
making for cancer patients. This dissertation is comprised of Chapter One, an introduction and 
review of the literature for relevant topics to this dissertation; Chapter Two, a systematic review 
describing clinical decision support (CDS) systems that have been used in clinical cancer settings 
to guide therapeutic decision making and the effect of CDS on care delivery process and patient 
outcomes; Chapter Three, a quantitative study describing the rate of guideline concordant care 
(GCC) provided for management of chemotherapy-induced nausea and vomiting (CINV) and 
identifying predictors of receiving GCC; and Chapter Four, a mixed-methods study evaluating 
the completeness, concordance, and heterogeneity of clinician documentation of CINV. Chapter 
Five is comprised of key findings of each study, the strengths and limitations, clinical and 
research implications, and future research. 
Summary of Results and Key Findings 
Chapter Two 
Chapter Two describes the first study of the dissertation.  The research question in this 
study was “What clinical decision support systems been tested in cancer settings to guide 
therapeutic decision making and in what ways were they successful?”  Through a systematic 
review of the literature guided by the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement, ten studies were identified that met the predetermined 
inclusion criteria. The study design varied, and the most common was pre-post interventional 
design (n=5). Seven studies were conducted in Europe; the remaining (n=3) in the United States. 
Of the ten studies, three used cancer treatment focused CDS interventions, and all studies 
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focused on breast cancer management. The remaining seven studies focused on symptom or 
supportive care management; the most common symptom studied was pain (n=3). Of the seven 
symptom or supportive care CDS studies, six incorporated patient-reported symptom information 
into the algorithm to inform the CDS recommendation to the clinician. Three of the ten studies 
used CDS systems that were integrated into the electronic health record (EHR) system, and all 
studies reported the CDS recommendations were informed by a published guideline.  
The outcomes measured also varied, and although all studies measured process outcome 
measures and/or patient outcomes, the measures utilized were not consistent. The most common 
process measure was adherence to the CDS recommendation, and the most common patient 
outcome measure was patient-reported pain. Through qualitative synthesis of the study results, 
we identified a trend in the ten included studies toward both provider- and patient-benefit from 
utilization of CDS. Of the nine studies that measured process outcome measures, five 
demonstrated a significant increase in utilizing the CDS recommendation. This was most 
commonly measured by clinician adherence to the CDS recommendation. Of the six studies that 
measured patient outcomes, four demonstrated significant improvement in patient outcomes; 
most of these were through patient-reported outcome measures (PROMs).  
Although there was variability in study design, CDS intervention, and outcome measures, 
this systematic review indicates that although CDS are a national focus to improve the quality of 
care, reduce errors, and increase shared decision making,102 the use of CDS in cancer therapeutic 
decision making has not been widely studied or published. Three of the ten studies were 
integrated into the electronic health record system, a known facilitator to guideline 
implementation.76 Also, five of the six studies incorporated PROMs into the CDS, and three of 
these found a significant benefit to either process and/or patient outcomes. Integration of PROMs 
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into clinical care, specifically through CDS integration, has been cited as a strategy to improve 
guideline implementation both broadly but also in cancer care delivery.115,130 
Chapter Three 
Chapter Three describes the second study of this dissertation. The research question in 
this study is, “What proportion of patients receiving emetogenic chemotherapy also receive 
guideline concordant care for the prevention of acute CINV?” To answer this question, we 
conducted a retrospective cohort study from 2016 – 2018 at a single institution and identified 
patients less than age 26 years who were receiving emetogenic chemotherapy.  Of the 180 
patients identified, 36% of patients received guideline concordant care prior to the administration 
of chemotherapy. These findings were further explored through bivariate and multivariable 
analysis, which found provider specialty, patient sociodemographic factors, and clinical factors 
(cancer type, chemotherapy regimen) were associated with receiving GCC.  
Patients who received care in pediatric oncology were significantly less likely to receive 
GCC compared to those treated in adult oncology (p<.0001). This finding may be due lack of 
knowledge about the guideline but also may be due to concerns about prescribing certain classes 
of drugs to children that may interact with chemotherapy. For example, the 2013 guideline for 
prevention of acute CINV in children with cancer, used to define GCC in this study, 
recommended the use of NK1RAs for patients age 12 and older due to limited data in children. 
In this study, of the 71 patients age 12 – 18 years, only 26% received the recommended NK1RA.  
Interestingly, a 2017 update of the guideline recommends using NK1RA for children over 6-
months of age, and only 10% of patients age 6-months to 12 years in this study received an 
NK1RA, suggesting protracted guideline implementation, widely recognized in the literature.74 
In addition to the slow dissemination of knowledge, discomfort prescribing this class of 
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medications may also be a barrier. Although an important class of drugs for CINV control, 
NK1RAs specifically have the potential to interact with other commonly-prescribed 
chemotherapy drugs, including ifosfamide, anthracyclines, and cyclophosphamide.196  
Another barrier to prescribing GCC in children is concern about concomitant medications 
related to their prescribed treatment, specifically dexamethasone.18 Because additional 
corticosteroids may be contraindicated in acute lymphoblastic leukemia and central nervous 
system tumors, the two most common types of childhood cancer, optimizing antiemetics is 
challenging in these patients. In contrast, the most common cancers in adults are solid tumors, 
and the same barriers to dexamethasone use do not exist.192 In a sub-group analysis only of 
patients with solid tumors, however, only 62% received dexamethasone. In addition, the 
alternative guideline recommended medications for when the primary recommended medications 
are not appropriate are known to have significant adverse effects and therefore may not 
commonly be used, and only 35% of patients in our study received additional anti-emetics. This 
may lead to undertreatment of CINV and potentially worse symptom management for children 
with cancer.  
Insurance status was also identified as a factor associated with receiving GCC, and 
patients who had commercial insurance were more likely to receive GCC (p=.02). This finding 
highlights potential disparities in prescribing that have been reported in adult breast cancer 
patients.66 In addition, a prior study in children with acute myeloid leukemia found a significant 
association of antiemetic rescue, prescribing an adjunct therapy for treatment of CINV, and 
insurance status; children with private insurance were significantly less likely to require rescue 
medication.48 Chapter Three in this dissertation supports this association, and insurance status 
may support a disparity in how CINV is assessed and/or managed.  
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Finally, type of chemotherapy regimen was identified as a factor related to receiving 
GCC, with patients receiving cisplatin-based regimens more likely to receive GCC (p=.01). This 
finding may be related to the historical knowledge of clinicians who recall that early studies 
testing antiemetics were conducted mostly in patients receiving cisplatin.188,244  This highlights 
another important area for future implementation and dissemination efforts. To optimize CINV 
prevention and management, providers should be aware of the emetogenicity classifications that 
are used to develop specific guideline recommendations, but an automated approach that 
prompts the guideline-based recommended anti-emetic regimen may also increase adherence to 
guidelines. Strategies to improve guideline awareness should include education, preferably 
interactive, audit-and-feedback, and clinical decision support integrated into the EHR.76 In 
summary, this second study reports a low-rate of guideline concordant care delivery for children, 
adolescents, and young adults receiving emetogenic chemotherapy and identifies factors to focus 
on for future improvement.  
Chapter Four 
Chapter Four describes the third study of this dissertation. In this study, the research 
question is “What is the status of documentation of CINV in the EHR specifically related to the 
completeness, concordance, and heterogeneity of the documentation?” EHR integration is an 
integral component of guideline implementation strategies such as CDS systems, and this study 
is a first step toward data-driven phenotyping methods used to identify patients with common 
diseases.216,217 To define a phenotype through a data-driven approach utilizing EHR data, the 
data quality of the available documentation or clinical characteristics must first be evaluated. To 
our knowledge, the data quality related to cancer symptoms, such as CINV, has not been 
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described, and phenotyping methods to identify patients at risk for CINV or experiencing CINV 
have not been developed.  
The purpose of this study was therefore to conduct a mixed-methods study to examine the 
completeness, concordance, and heterogeneity105,208 of the documentation in the EHR of 127 
children, adolescents, and young adults receiving highly-emetogenic chemotherapy. The results 
showed that, although most clinicians documented an assessment acknowledging the presence or 
absence of CINV (75% for prescribers; 58% for RNs), a complete assessment of CINV was not 
documented in many patients. Specifically, the symptom’s severity and temporality were usually 
not documented. Regarding the concordance of documentation, of patients where both a 
prescriber and RN documented an assessment of CINV (n=60), 72% were concordant. When 
comparing the ICD-10 billing codes with the prescriber documentation, of the 95 patients where 
a prescriber assessed CINV, 50% of the ICD-10 codes were concordant. Of the 20 patients where 
an ICD-10 code for CINV was present, 85% were in agreement with the prescriber 
documentation. In contrast, the ICD-10 codes for primary cancer diagnosis were correct in 100% 
of patients.  
By mapping the concept of CINV through the United Medical Language System and 
utilizing our findings from the EHR documentation as well as validated measures to assess 
CINV, we developed a post-coordination approach that would identify the presence or absence 
of CINV in 85% of prescriber documentation and 100% of RN documentation.  This approach, 
however, did not fully capture the granularity of CINV status related to the severity and 
temporality. Integrating patient-reported outcome measures into the EHR is a potential strategy 
to increase the completeness of the documentation of CINV.115,236 This study contributes new 
knowledge to the field of phenotyping cancer-related symptoms and provides a framework for a 
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CDS system to improve adherence to CINV guidelines for pediatric, adolescent, and young adult 
patients with cancer.  
Strengths and Limitations 
 This dissertation has some strengths and limitations. A major strength of the dissertation 
is that it provides a comprehensive assessment of CINV management in children, adolescent, and 
young adults with cancer and includes possible methods to address the low adherence to GCC. 
We identified a low rate of GCC in this understudied population, evaluated CDS interventions 
previously utilized for cancer management, and then assessed the current documentation of 
CINV in the EHR. The results of this dissertation support that incorporating CDS infrastructure 
into the EHR to improve CINV assessment and management may be feasible.  
 Another strength of this study is the level of granularity that was leveraged in Studies 
Two and Three. In Study Two, patient-level data strengthened the internal validity of the 
findings because the prescribing and administration of anti-emetics could be confirmed through 
the EHR. Studies that utilize larger datasets, such as through insurance claims, are generally not 
able to provide this level of detail. In addition, Study Two compared anti-emetic prescribing and 
administration by two distinct provider specialties (i.e. pediatric oncology, adult oncology), and 
the patient-level data that was utilized to describe these characteristics further strengthens this 
study. The clinical practice or setting where a patient receives treatment may be difficult to 
accurately describe from a larger dataset.  
Similarly, the ability to assess the heterogeneity of the EHR documentation through 
direct EHR navigation, and the completeness and concordance of the EHR documentation 
through abstracting multiple clinical notes, structured data, and billing codes is a major strength 
of Study Three. The granularity that could be assessed through patient-level records in the EHR 
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provided a more complete understanding of the data. These data are not routinely available 
through large datasets.  
 An important limitation of this dissertation is the limited generalizability. In Study 
Three, the documentation patterns and locations of documentation may vary by EHR system. 
Future studies should include assessment of the data quality to determine if the concept mapping 
and post-coordinated expression are useful across EHR systems. The use of standardized 
terminologies and mapping through UMLS should be generalizable across EHR systems, 
however, because the symptom definitions and patient-characteristics are universal to CINV.  
Similarly, because this dissertation utilized data from a single institution, these results 
may not be generalizable across multiple settings, specifically the independent variables that 
were significantly associated with receiving GCC. The institution is a large hospital system, 
NCI-designated Comprehensive Cancer Center, and a Minority-Underserved NCI-Community 
Oncology Research Program. It provides care to a diverse population that includes a significant 
proportion of children, adolescents, and young adults in the metropolitan New York City area 
with cancer. Future studies should explore risk factors for CINV in non-urban, rural, and 
community oncology practices to determine external validity of the identified associations with 
receiving GCC.  
Another limitation of this study is that we focused on one cancer symptom, CINV, to 
further explore decision making processes and documentation in cancer care delivery. This 
symptom was chosen because there are effective strategies to prevent and manage CINV and it is 
one of the most commonly-reported symptoms that affects quality of life and may reduce 
adherence to treatment regimens. The findings may not be generalizable to other cancer 
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symptoms. We hypothesize that at least in part, these methods and findings can support future 
work in other common cancer symptoms, such as fatigue, pain, and mucositis.  
Implications and Future Research 
The implications of this dissertation research include both clinical and policy 
considerations, and these should be used to inform future work in guideline implementation 
using informatics-based approaches in pediatric, adolescent and young adult cancers.  
Research Implications 
First, CDS may be a beneficial intervention to guide decision making and improve 
knowledge translation from evidence base into pediatric, adolescent and young adult cancer 
clinical care, specifically for CINV prevention and management. Although CDS interventions 
have not yet been conducted and published in pediatric settings, tools have been developed and 
validated and are ready for future implementation studies. For example, the Supportive care 
Assessment, Prioritization and Recommendations for Kids (SPARK) is a web-based tool to 
facilitate symptom screening in children and adolescents with cancer with the capability to 
provide both provider- and patient-friendly feedback from guideline recommendations.245,246  
These studies demonstrate that this tool is feasible and usable from a patient-perspective as a 
symptom screening tool for children ages 8 – 18 years of age. Although this symptom screening 
tool has not been tested as a CDS for clinicians, this work is promising and suggests that CDS 
systems will continue to be developed and tested for children and adolescent cancer symptom 
management. Symptom screening in general and specific symptom screening can be linked to 
CDS, similar to the studies identified in our systematic review.153-157,247 Importantly, none of 
these CDS interventions were developed for or tested in children or adolescents.   
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Another opportunity for future research is to intervene on the system rather than the 
provider or patient. The findings from Study Two identified provider specialty as a significant 
predictor of receiving GCC, and future studies should explore the feasibility of modifying the 
order entry system to automatically default to the guideline-recommendations for anti-emetic 
depending on emetogenic classification of the regimen. Study Three provides the building blocks 
needed to identify patients at risk for CINV, including ICD-10 diagnostic codes and RxNorm 
medication codes. By setting the default for a computerized provider order entry system to the 
appropriate antiemetic regimen, this may alleviate the workflow concerns that may be associated 
with a true CDS intervention. One example of a study that intervened at the system-level 
includes S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) 
(NCT02728596) through the NCI’s Cancer Care Delivery network. This cluster-randomized 
study is currently accruing patients and randomizes to usual care or an EHR modification to 
prescribe a medication to patients who meet guideline criteria by default. A similar study may be 
an appropriate strategy to improve guideline adherence for CINV prevention.  
Clinical Implications 
Another implication of this dissertation is the clinical impact of the low rate of GCC and 
specific multi-level factors associated with receiving GCC for prevention of acute CINV. 
Provision of GCC reduces CINV symptoms, therefore it is likely that the low rate of GCC may 
correlate to increased symptom burden and lower quality of life for children with cancer. This 
finding highlights the importance of supporting provider education and implementation strategies 
for CINV guidelines. The findings from this dissertation align with ongoing initiatives through 
the Children’s Oncology Group (NCT02847130) and across the NCTN network (NCT03204916) 
to identify and address barriers to guideline implementation for children, adolescence and young 
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adults with cancer. In addition, the results of this dissertation provide new knowledge, and 
factors identified in this study that are associated with not receiving GCC which should be 
validated and ultimately, used to inform future implementation interventions, such as audit and 
feedback, or development of CDS tools.  
Policy Implications 
In addition to the clinical implications of low rates of GCC for CINV in children, 
adolescents, and young adults, the policy and regulatory implications of these studies are 
important. Pediatric cancer is relatively rare and makes up only 1% of cancer cases.248 However, 
children are diagnosed at an average age of 6 years, and with 80% expected to become long-term 
survivors, symptom management and reduction of morbidity is essential. Four percent of federal 
cancer research funding goes to pediatric cancer, and pharmaceutical companies fund very little 
drug development in pediatrics.249  
This has been due to financial and regulatory concerns.199,204  In general, profits from 
pediatric medications when few children require medications are generally low. In addition, 
conducting clinical trials in pediatric settings require additional regulatory and clinical 
considerations that may be perceived as barriers to pharmaceutical companies. New regulations, 
specifically the Best Pharmaceuticals for Children Act, aim to incentive pharmaceutical 
companies to provide pediatric-specific data and apply for pediatric indications. In fact, an 
increase in pediatric-specific indications has been noted, with most of these being anti-tumor 
drugs. These initiatives should continue to provide funding for this important, vulnerable 
population to ensure that supportive care medications are also developed, tested and approved to 
reduce morbidity and improve long-term outcomes.  
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 Further, because effective medications are readily available to prevent and manage 
CINV, further studies are needed to understand their use and safety in children and adolescents. 
Specifically, post-marketing studies should be supported and conducted to characterize the true 
risks of concomitant medications, such as those identified with NK1RAs and chemotherapy.196 
Finally, because dexamethasone may not be allowed for children with the most common 
pediatric cancers, further studies should focus on developing the most effective combination of 
anti-emetics for this group of patients who, in practice, are precluded from receiving GCC.  
Informatics Implications 
 Finally, an important implication to acknowledge is the potential for post-coordination 
expression to correctly identify at-risk and patients with CINV.  By harnessing the findings from 
our systematic review that EHR integration is an integral component of guideline 
implementation strategies such as CDS systems, Study Three of this dissertation demonstrated 
that although documentation is heterogeneous, frequently incomplete and discordant by provider 
type, characteristics in the EHR are documented that can be utilized to classify the symptom, at 
least in part, through available terminologies and data-driven approaches. This study provides 
baseline data for further development of a phenotyping algorithm and validation testing across 
multiple EHR systems. 
 The importance of CDS tools to improve healthcare delivery is clearly stated by the 
recent National Academy of Medicine in “The Learning Health System Series: Optimizing 
Strategies for Clinical Decision Support.”102 The panel acknowledges the importance of EHR 
data to inform CDS and that commitment to interoperability and collaboration across multiple 
stakeholders will be necessary to move the field forward. Specifically, understanding and 
developing a set of standards, including data standards for EHR are an integral component. The 
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findings from Study Three provide a step toward developing data quality standards for cancer 
symptom documentation in the EHR.  
Conclusion 
In conclusion, this dissertation described three studies to better characterize clinician 
decision making in cancer care delivery. This work is timely and important due to national 
efforts to improve the implementation of evidence into clinical practice. The findings from this 
dissertation support ongoing initiatives to improve implementation of the evidence base into 
cancer care delivery for children, adolescents, and young adults with cancer and to inform future 
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Appendix A: Search Strategy for Systematic Review 
Database Search Terms Initial publications 
retrieved 
Pubmed ("neoplasms"[MeSH Terms] OR 
("neoplasms"[MeSH Terms] OR 
"neoplasms"[tiab] OR "cancer"[tiab])) AND 
(automated[tiab] OR ("electronics"[MeSH 
Terms] OR "electronics"[tiab] OR 
"electronic"[tiab])) AND ("decision support 
techniques"[MeSH Terms] OR ("decision"[All 
Fields] AND "support"[All Fields] AND 
"techniques"[All Fields]) OR "decision support 
techniques"[All Fields] OR ("decision"[All 
Fields] AND "aid"[All Fields]) OR "decision 
aid"[All Fields]) 
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Embase ('clinical decision support':ab,ti OR 'clinical 
decision support'/exp/mj OR 'decision 
aid':ab,ti OR 'decision aid'/exp/mj OR 'clinical 
decision support system'/exp/mj OR 'expert 
system':ab,ti OR 'expert system'/exp/mj) AND 
('cancer':ab,ti OR 'neoplasm'/exp/mj) AND 










Appendix B: Chemotherapeutic Agents Classified as Highly- or Moderately 
Emetogenic175,178 
Emetogenicity Chemotherapeutic Agent 1 AND Agent 2 (if applicable) 
High Cisplatin n/a 
 Carboplatin* n/a 
 Dacarbazine n/a 
 Dactinomycin* n/a 
 Procarbazine n/a 
 Cyclophosphamide Doxorubicin 
 Cyclophosphamide Etoposide* 
 Ifosfamide Etoposide* 
 Thiotepa ≥ 300mg/m2* n/a 
 Cytarabine 3g/m2/dose* n/a 
 Cyclophosphamide ≥ 1g/m2* n/a 
 Methotrexate ≥ 12g/m2 n/a 
Moderate   
 Aldesleukin >12 to 15 million 
U/m2 
n/a 
 Arsenic trioxide n/a 
 Azacitadine n/a 
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 Bendamustine n/a 
 Busulfan n/a 
 Carmustine <250mg/m2 n/a 
 Clofarabine Etoposide 
 Cyclophosphamide <1g/m2 n/a 
 Daunorubicin n/a 
 Doxorubicin n/a 
 Epirubicin n/a 
 Etoposide (oral) n/a 
 Idarubicin n/a 
 Imatinib (oral) n/a 
 Ifosfamide n/a 
 Intrathecal chemotherapy (MTX, 
HCT, Ara-C) 
n/a 
 Irinotecan n/a 
 Lomustine n/a 
 Melphalan n/a 
 Methotrexate 250mg/m2 – 12g/m2 n/a 
 Oxaliplatin >75mg/m2 n/a 
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 Temozolomide (oral) n/a 
 Vinorelbine (oral) n/a 




Appendix C: Anti-emetics Included in Retrospective Cohort Study 
Antiemetic Class of drug Guideline-recommended 
Ondansetron 5HT3-receptor antagonist Yes 
Granisetron 5HT3-receptor antagonist Yes 
Palonosetron 5HT3-receptor antagonist Yes 
Aprepitant Neurokinin1-receptor antagonist Yes, with exceptions 
Fosaprepitant Neurokinin1-receptor antagonist Yes, with exceptions 
Dexamethasone Corticosteroid Yes, with exceptions 
Olanzapine Atypical antipsychotic Yes, with exceptions 
Lorazepam Benzodiazepine Not for acute CINV 
Metoclopramide Prokinetic Not for acute CINV 
Prochlorperazine 1st generation antipsychotic Not for acute CINV 
Chlorpromazine Phenothiazine antipsychotics Not for acute CINV 
Nabilone Synthetic cannabinoid Not for acute CINV 
Dronabinol Synthetic cannabinoid Not for acute CINV 
Diphenhydramine Antihistamine Not for acute CINV 
Hydroxyzine Antihistamine Not for acute CINV 
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Appendix D. Information of interest in EHR 




Follow-up Visit (Pediatric and 
Adult Oncology) 
Home Medication List 
History of present illness (HPI) 
Problem list (active) 
GI medication prescriptions 
• CINV assessed
• CINV present
• Free text from HPI
• ICD-10 code for CINV
• ICD-10 code for primary disease




Pediatric Oncology Note 
Ob/Gyn Encounter Note 
Medicine Resident Progress Note 
Hem/Oncology Attending Follow-
up Note 
History of present illness 
Problem list (active) 
Clinical summary (ICD-10 codes) 
• CINV assessed
• CINV present
• Free text from HPI
• ICD-10 code for CINV
• ICD-10 code for primary disease
• ICD-10 code for antineoplastic visit
Nursing 
documentation 





Medication Administration Record 




Chemotherapeutic and antiemetic 
agents administered in clinic 
• Nausea/vomiting present (Y/N)
(text)
• Medication given (Y/N) (Drug)
• Chemotherapy type
• Confirm class of emetogenicity is
HEC
• Appropriate regimen administered
in clinic (Y/N)
